Cover Page for Protocol J1365  
NCT Number  [STUDY_ID_REMOVED]  
Offic ial Title of Study  Study of MK -3475 (an Antibody That Blocks Negative Signals 
to T Cells) in Patients With Microsatellite Unstable (MSI) 
Tumors (Cohort D ) 
Document Date  August 7,  2020  
 
    TITLE:
 
Phase 2 Study of MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
 
 
Johns Hopkins
 
Protocol #:
 
 
J1365
, NA_
00085756
 
 
[COMPANY_006] Protocol #:
 
MK
-
3475
-
016
 
 
Coordinating 
Center:
 
 
 
Sidney Kimmel Comprehensive Cancer Center, 
 
 
 
 
 
 
 
 
 
 
Johns Hopkins University
 
 
Key Principal Investigator:
 
[INVESTIGATOR_685567]
, M.D.
 
(Protocol Chair)
 
(Johns Hopkins)
 
 
 
 
 
 
 
 
 
Principal Investigator
s
:
 
Rachel Sanborn
, 
M.D., 
Providence Medical Center
 
(Other Sites)
 
 
 
George Fischer, 
M.D., Ph.D., 
Stanford University
 
 
 
 
 
Tim Greten, 
M.D., 
National Cancer Institute
 
 
John Hays
, 
M.D., 
The Ohio State University
 
 
 
 
 
Anuradha Krishnamurthy
, 
M.D.
, 
University of Pi[INVESTIGATOR_685568], M.D., University of Pennsylvania
 
Clare 
Friedman
, M.D., 
Memorial Sloan Kettering
 
Cancer Center
 
 
 
[COMPANY_006]
 
Supplied Agent
:
 
MK
-
3475
 
 
IND:
 
 
 
 
 
 
 
 
 
IND 
118566
 
 
IND Sponsor:
 
Dung Le
, M.D.
 
 
 
 
 
 
 
 
 
 
 

Phase 2 Study of MK
-
3475 in Patients 
with Microsatellite Unstable (MSI) Tumors
 
Amendment 
1
3
/ Version 1
4
/ 
August 
7, 2020
 
 
2
Protocol 
Type / 
Version 
# / Version 
Date:
 
Original/ Version 1/ 
May 1, 2013
 
Original/ Version 1.1/ May 30, 2013
 
Amendment 1/ Version 2/ July 18, 2013
 
Amendment 2/ Version 3/ September 19, 2013
 
Amendment 3/ Version 4/ January 13, 2014
 
Amendment 4/
 
Version 5/ March 18, 2014
 
Amendment 5/ Version 6/ 
May 5, 2014
 
Amendment 6/ Version 7/ 
November 
19
, 2014
 
Amendment 7/ Version 8/ 
May 1
, 2015
 
Amendment 8/ Version 9/ November 20, 2015
 
Amendment 9/ Version 10/
 
January 3, 2017
 
Amendment 10
/ Version 1
1
/
 
February 9, 2017
 
Amendment 11
/ Version 1
2
/
 
December 1, 2017
 
Amendment 12
/ Version 1
3
/
 
January 17, 2020
 
Amendment 13
/ Version 1
4
/
 
August 7, 2020
 
 
 
 
 
 
 
 
 
Phase 2 Study of MK
-
3475 in Patients 
with Microsatellite Unstable (MSI) Tumors
 
Amendment 
1
3
/ Version 1
4
/ 
August 
7, 2020
 
 
3
SCHEMA
 
 
 
 

Phase 2 Study of MK
-
3475 in Patients 
with Microsatellite Unstable (MSI) Tumors
 
Amendment 
1
3
/ Version 1
4
/ 
August 
7, 2020
 
 
4
TABLE OF CONTENTS
 
SCHEMA
 
................................
................................
................................
................................
.........
3
 
1.
 
OBJECTIVES
 
................................
................................
................................
......................
7
 
1.1
 
Primary Objectiv
es
................................
................................
................................
...
7
 
1.2
 
Secondary Objectives
................................
................................
...............................
7
 
1.3
 
Exploratory Objectives
 
................................
................................
............................
7
 
1.4 
 
Study Design
 
................................
................................
................................
............
8
 
2.
 
BACKGROUND
 
................................
................................
................................
...............
11
 
2.1
 
Study Disease
 
................................
................................
................................
.........
11
 
2.2
 
MK
-
3475
 
................................
................................
................................
................
11
 
2.3
 
Preclinical and 
Clinical Trial Data
 
................................
................................
.........
13
 
2.4
 
Rationale
 
................................
................................
................................
................
13
 
3.
 
PATIENT SELECTION
 
................................
................................
................................
....
14
 
3.1
 
Eligibility Criteria
 
................................
................................
................................
..
14
 
3.2
 
Exclusion Criteria
 
................................
................................
................................
..
16
 
3.3
 
Inclusion of Women and 
Minorities
 
................................
................................
......
18
 
3.4 
 
MSI Testing
 
................................
................................
................................
...........
18
 
3.5 
 
Testing for high mutational burden
................................
................................
........
19
 
4.
 
REGISTRATION PROCEDURES
 
................................
................................
...................
19
 
4.1 
 
General Guidelines
................................
................................
................................
.
19
 
4.2
 
Registration Process
 
................................
................................
...............................
19
 
5.
 
TREAT
MENT PLAN
 
................................
................................
................................
........
20
 
5.1
 
Agent Administration
................................
................................
.............................
20
 
5.2
 
General Concomitant Medication and Supportive Care Guidelines
 
......................
20
 
5.3 
 
Dosing Criteria
 
................................
................................
................................
.......
23
 
5.4
 
Definition of an Overdose for this Protocol
 
................................
...........................
23
 
5.5
 
Contraception, Use in Pregnancy, Use in Nursing
 
................................
................
24
 
5.6
 
Duration of Therapy
 
................................
................................
...............................
25
 
5.7
 
Off Tr
eatment Evaluation and Retreatment Criteria
 
................................
..............
26
 
5.8
 
Off Study/
Safety Follow
-
up Visit
 
................................
................................
..........
27
 
5.9
 
Duration of Follow Up
 
................................
................................
...........................
27
 
5.10
 
Cri
teria for Removal from Study
 
................................
................................
...........
28
 
6.
 
DOSING DELAYS/DOSE MODIFICATIONS
 
................................
...............................
30
 
6.1 
 
Dose Modifications
 
................................
................................
................................
30
 
6.2 
 
Dosing Delays
 
................................
................................
................................
........
30
 
7.
 
ADVERSE EVE
NTS:  LIST AND REPORTING REQUIREMENTS
 
............................
34
 
7.1
 
Definitions
................................
................................
................................
..............
34
 
7.2
 
Relationship
 
................................
................................
................................
...........
36
 
7.3
 
Expectedness
 
................................
................................
................................
..........
36
 
7.4
 
Handling of Expedited Safety Reports
 
................................
................................
..
37
 
Phase 2 Study of MK
-
3475 in Patients 
with Microsatellite Unstable (MSI) Tumors
 
Amendment 
1
3
/ Version 1
4
/ 
August 
7, 2020
 
 
5
7.5 
 
Reporting
................................
................................
................................
................
37
 
8.
 
PHARMACEUTICALINFORMATION (MK
-
3475)
 
................................
.......................
39
 
8.1
 
Agent Accountability
 
................................
................................
.............................
39
 
8.2
 
Mode of Action
 
................................
................................
................................
......
39
 
8.3
 
Description
 
................................
................................
................................
.............
39
 
8.4
 
Packaging and 
Labeling Information
 
................................
................................
.....
39
 
8.5
 
Preparation
 
................................
................................
................................
.............
39
 
8.6
 
Storage
 
................................
................................
................................
...................
39
 
8.7
 
Stability
 
................................
................................
................................
..................
40
 
8.8
 
Route of Adminis
tration
 
................................
................................
........................
40
 
8.9
 
Patient Care Implications
 
................................
................................
.......................
40
 
8.10
 
Agent Ordering
 
................................
................................
................................
......
40
 
8.11 
 
Returns 
and Reconciliation
 
................................
................................
....................
41
 
9.
 
CORRELATIVE/SPECIAL STUDIES
 
................................
................................
.............
41
 
9.1
 
Tumor Tissue Studies
 
................................
................................
............................
41
 
9.2 
 
Peripheral Blood Lymphocytes (PBLs)
 
................................
................................
.
[ADDRESS_929277] 
–
 
Solid Tumors
 
................................
................................
..........
50
 
12.
 
 
DATA REPORTING / REGULATORY REQUIREMENTS
 
................................
..........
52
 
12.1
 
Data Management
 
................................
................................
................................
..
52
 
12.2
 
Safety Meetings
 
................................
................................
................................
.....
53
 
12.3 
 
Monitoring
 
................................
................................
................................
.............
53
 
13.
 
STATISTICAL CONSIDERATIONS
................................
................................
...............
54
 
13
.1
 
Study Design/Endpoints
................................
................................
.........................
54
 
13.2
 
Sample Size/Accrual Rate
 
................................
................................
......................
54
 
13.3
 
Stratification Factors
 
................................
................................
..............................
56
 
13.4
 
A
nalysis of Primary Endpoints
 
................................
................................
..............
56
 
13.5
 
Analysis of Secondary Endpoints
 
................................
................................
..........
57
 
13.6
 
Safety Analysis
 
................................
................................
................................
......
58
 
13.7
 
Biomarker Analysis
 
................................
................................
...............................
59
 
REFERENCES
 
................................
................................
................................
..............................
61
 
APPENDIX A: Performance Status Criteria
 
................................
................................
.................
66
 
Phase 2 Study of MK
-
3475 in Patients 
with Microsatellite Unstable (MSI) Tumors
 
Amendment 
1
3
/ Version 1
4
/ 
August 
7, 2020
 
 
6
APPENDIX B: Foundation One Tumor Mutational Burden (TMB) Testing
................................
67
 
APPENDIX C: Adverse Event of Clinical Interest (ECI) Reporting Form
 
................................
...
68
 
APPENDIX D: SAE Reporting Form
 
................................
................................
...........................
71
 
APPENDIX E: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria for 
Evaluating Response in Solid Tumors
 
................................
................................
...............
74
 
APPENDIX F: Immune Related Response Criteria
 
................................
................................
......
77
 
 
 
 
 
 
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
7
1.
 
OBJECTIVES
 
 
1.1
 
 
Primary Objectives
 
 
1.1.1
 
Cohorts A and B: 
To 
determine
 
the 
immune
-
related 
progression
 
free survival 
(
ir
PFS)
 
rate
 
at 
20
 
weeks and 
objective response rate (irORR) 
in
 
patients with 
MSI positive 
and negative 
colorectal adenocarcinoma
 
treated with MK
-
3475
 
using 
immune related response criteria (
irRC
)
 
during stages 1 and 2
.
 
 
 
1.1.2
 
Cohort C: 
To determine the 
immune
-
related progression free survival (irPFS) 
rate
 
in patients with 
MSI positive non
-
colorectal 
solid tumor malignancies
 
treated with MK
-
3475 using immune relate
d response criteria (irRC) at 
20
 
weeks
 
during stages 1 and 2
.
 
 
 
1.1.3
 
Cohorts A and C: 
To determine the 
progression free survival (PFS) rate
 
at 20 
weeks and 
the 
objective response rate (ORR) 
in patients with MSI positive solid 
tumor malignancies treated with 
MK
-
[ADDRESS_929278] 1.1
 
criteria during 
the second expansion
.
 
 
1.1.4
 
Cohort D: 
To estimate 
objective
 
response rate
 
in patients with MSI
-
negative 
solid tumor malignancies with a mutator phenotype (i.e. high mutational 
burden) treated with MK
-
[ADDRESS_929279] treatment response.
 
 
1.3
 
Exploratory Objectives
 
 
1.3.1 
To explore the association of MSI positive, PD
-
L1 
positivity, and tumor 
infiltrating lymphocyte characteristic
s
 
with clinical responses.
 
Archived tumor 
tissue (when available) 
and
 
tumor tissue obtained 
at baseline and during
 
treatment
 
will be compared
.
 
In addition, we will compare differences in PD
-
L1 
expression between the primary and secondary sites of cancer.
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929280] peripheral blood lymphocytes 
to explore the association of MSI 
positive, PD
-
1 positivity, and lymphocyte activation markers with clinical 
responses
.  
 
 
1.3.6
 
To determine alternative markers of MSI status
. Th
is includes but is not limited 
to MLH 1, MSH 2, MSH 6, PMS2, BRAF pV600E, and TGFBR2.
 
 
1.4 
 
Study Design
 
 
This is a 
multi
-
center, open label, 
two
-
stage, 
phase 
2 
study to evaluate the clinical 
activity of MK
-
3475 in MSI positive and MSI negative solid 
tumors
.  
We will enroll 
four
 
cohorts of patients to receive MK
-
3475:  patients with MSI positive colo
rectal 
adenocarcinomas
 
(Cohort A); patients with MSI negative colo
rectal adenocarcinomas
 
(Cohort 
B); and patients with MSI positive solid tumor 
malignancies 
but not colo
rectal 
adenocarcinoma
 
(Cohort C)
; and patients with MSI
-
negative solid tumor malignancies 
that have a mutator phenotype (Cohort D)
. MK
-
3475 will be administered at 10 mg/kg 
every 
[ADDRESS_929281] 
two
 
affe
cted
 
loci
[1,
 
2]
.
 
 
Patients 
in Cohorts A, B, and C 
will be evaluable if they receive 
one dose of MK
-
3475 and if MSI results are confirmed using the MSI Analysis System 
from Promega (
S
ection 3.4
). 
With amendment 9, the decision was made to not require 
retesting with Promega
 
if MSI status is confirmed by [CONTACT_270212]
.
 
 
Eligibility for Cohort D will be determined using a 
CLIA certified test 
measuring 
mutational burden
.
 
Patients in Cohort D will be evaluable if they receive one dose of 
MK
-
[ADDRESS_929282]
 
a 
MSI
-
negative solid tumor malignancies with a documented 
mutation burden level measured at 
>
 
2
0 mutations per megabase pairs (MB) using the 
Foundation Medicine (FoundationOne.com) targeted sequencing panel that reports 
mutation burden.
 
 
 
The primary endp
oint
s
 
for Cohort
s
 
A
 
and B
 
are
 
immune
-
related progression
-
free 
survival (irPFS) rate 
at 
20
 
weeks and objective response rate (irORR) 
assessed using 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
9
immune related response criteria (irRC)
; irPFS is
 
defined as the proportion of subjects 
alive and free of dis
ease progression at 
20
 
weeks per irRC;
 
and irORR is the proportion 
of subjects whose best overall response is a CR or PR.
 
Each cohort will be assessed 
separately.  
 
 
The primary endpoint 
for Cohort C 
is immune
-
related progression
-
free survival (irPFS) 
rate 
assessed using
 
immune related response criteria (irRC) at 
[ADDRESS_929283] for 
further evaluation if the irPFS rate at 
20
 
weeks is 5% (p
10
) or less 
or irORR is 5% (
p
20
)
 
or less, 
and considered active if the irPFS rate at 
20
 
weeks is 25% or greater (p
1
1
)
 
and 
irORR is 
2
1
% or greater (
p
21
)
.
 
The endpoints will be tested in the hierarchical order 
first with irPFS at 
20
 
weeks. If the null hypothesis of 
20
-
week irPFS being 5% is 
rejected (i.e. the result reaches statistical significance), we will proceed to test for 
irORR. If
 
irPFS is not significant at the 0.05 level (one
-
sided test), the statistical testing 
for irORR will not occur. 
 
 
A two
-
stage Green
-
Dahlberg design 
is 
used for 
C
ohort
 
A
 
and B
. 
An interim analysis 
will be conducted in order to assess futility after irPFS at 
[ADDRESS_929284] for the endpoint of irORR 
in that c
ohort. If 4 or more responders (CR 
or PR) are observed, we conclude the regimen is pro
mising 
with that cohort 
and 
warrant
s
 
further study
 
for 
that cohort
.
 
 
For Cohort C, MK
-
[ADDRESS_929285] for further 
evaluation if the irPFS rate at 
20
 
weeks is 5% (p
0
) or less and considered active if the 
irPFS rate at 
20
 
weeks is 25% or greater (p
1
). 
 
 
A two
-
stage Green
-
Dahlberg design 
is
 
used for Cohort C. 
An interim analysis will be 
conducted in order to assess futility after irPFS at 
[ADDRESS_929286] one patient is free of disease progression at 
20
 
weeks per irRC, 
an additional 
7 
evaluable 
subjects will be enrolled
 
in
to
 
Cohort C
. If 3 or fewer p
atients 
are progression free at 
20
 
weeks in the total of 
21 
evaluable 
patients enrolled in 
C
ohort
 
C
, then the regimen will be considered inactive in that cohort. If 4 or more patients are 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929287] 1.1 criteria only
, and ORR will be the primary 
endpoint for the expanded Cohort A and 
Cohort C
.
 
 
For Cohort D, 
t
he regimen would be considered of insufficient activity for further study 
if 
the response rate is 5% or less, and the minimum required level of efficacy that would 
warrant further study with the proposed regimen is a 21% response 
rate. A two
-
stage 
Green
-
Dahlberg design is planned. 
A
 
total of [ADDRESS_929288] 
stage. 
If zero response is observed, that cohort will be terminated and we will conclude 
the regimen is ineffective. If 
>
1 subjects respond, then additi
onal 15 subjects will be 
studied for that cohort.  If 
<
 
4 subjects respond in stage one and two combined, we 
consider this regimen ineffective. If 
>
5 responses are observed, we conclude the 
regimen is promising and warrant further study. Each cohort could 
also be terminated 
as soon as 5 responses are observed before the total cohort is enrolled o
r
 
evaluated in 
that cohort. The maximum sample size will be 35 for each cohort. This design provides 
90% power to detect an absolute difference of 16% of response w
ith a type I error of 
0.05. There is a 36% chance to stop the trial early for futility under 5% response rate.
 
 
No intra
-
subject dose escalation or reduction is allowed.
  
Patients who do not receive 
at least 1 dose of MK
-
3475 will be replaced.
 
 
Patient imm
une and clinical responses will be evaluated through the following methods
 
at baseline and during treatment
: 1. 
tumor biopsies, 
2. peripheral blood lymphocytes, 
3. serum and plasma, 
and 
[ADDRESS_929289]
/MRI
 
scans will be obtained for assessment of activity 
and correlative studies. 
 
 
Patients who have a confirmed complete response by [CONTACT_270213] 
≥ [ADDRESS_929290] imaging or laboratory parameter
s prior to 
their 
7 
month evaluation but without rapid clinical deterioration or 
significant 
change 
in 
performance status
 
who do not require additional immediate therapy, may continue 
to be treated with MK
-
3475 and clinically observed following the assigned
 
imaging 
schedule to allow detection of a subsequent tumor response
 
(see 
Section 5.10.1
 
for 
further details)
. 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929291] dose of study drug 
(serious adverse events will be collected for [ADDRESS_929292] infusion of MK
-
3475
) 
or until initiation of a new anti
-
cancer treatment, whichever occurs first.
 
Patients who are discontinued from the study due to an unacceptable drug
-
related AE 
will b
e followed until the resolution of the AE to Grade [ADDRESS_929293] come off study 
without
 
docume
nted disease progression
 
(or to 
receive the FDA approved dose of pembrolizumab for microsatellite instability
-
high 
cancer)
 
should continue to be monitored for disease status by [CONTACT_70719].  
Disease monitoring should continue to be assessed 
approximately every 
12 weeks 
for 
3 years
, followed by 
[CONTACT_605507] 6 months after 3 years
 
and
 
annually after 5 
years
 
(timing calculated from the first dose of MK
-
3475
)
 
until, 1) start of a new 
antineoplastic therapy (information of the new cancer th
erapy will be collected), 
2
) 
documented disease progression, 
3) study closure, 
or 4) until death, whichever occurs 
first.
 
 
Patients who 
are off study
 
should be contact[CONTACT_685584] 3 
years
, followed by 
[CONTACT_605507] 6 months
 
after 3 years
 
and annually after 5 
years
 
(timing calculated 
from the first dose of MK
-
3475
)
 
to monitor overall survival.  
Information of other cancer therapi[INVESTIGATOR_685569].
 
 
2.
 
BACKGROUND
 
 
2.1
 
Study Dis
ease
 
 
Microsatellite instability (MSI) is the accumulation of sequencing errors in 
microsatellites.  This occurs in tumors with deficiency in DNA mismatch repair.  MSI 
is present 
in 
Lynch Syndrome which is an inherited cancer syndrome that predisposes 
patients to colon, endometrial, gastric cancer, ovarian, small intestine, liver, 
hepatobiliary, upper urinary tract, brain, and prostate cancer.  MSI is also present in 10
-
20% of sporadic colorectal
 
[
3
]
, gastric
 
[
4
]
, prostate 
[
5
]
, lung 
[
6
, 
7
]
, ampullary [
8
], and 
endometrial cancers [
9
]
.   Between 0.3% and 13% of pancreatic cancers are reported to 
be MSI as well
 
[
10
]
.
 
The study is designed to test an immunotherapy in MSI 
colorectal 
adenocarcinomas
 
with an additional exploratory cohort in other MSI disease ty
pes. 
 
 
2.
[ADDRESS_929294] immune surveillance in controlling outgrowth of neoplastic 
transformation has been known for decades [
11
].  Accumulating evidence shows a 
correlation between tumor
-
infiltrating lymphocytes (TILs) in cancer 
tissue and 
favorable prognosis in various malignancies [
12
-
47
].  In particular, the presence of 
CD8
+
 
T
-
cells and the ratio of CD8
+
 
effector T
-
cells / FoxP3
+
 
regulatory T
-
cells seems 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
12
to correlate with improved prognosis and long
-
term survival in solid malig
nancies such 
as ovarian, colorectal and pancreatic cancer, hepatocellular carcinoma, malignant MEL 
and RCC.  TILs can be expanded 
ex vivo
 
and re
-
infused, inducing durable objective 
tumor responses in cancers such as 
melanoma
 
[
48
; 
49
].
 
 
The PD
-
[ADDRESS_929295] hijacked by [CONTACT_70710] 
[
11
].  
 
The normal function of PD
-
1, expressed on the cell 
surface of activated T
-
cells under healthy conditions, is to down
-
modulate unwanted 
or excessive immune responses, 
including autoimmune reactions. 
The ligands for PD
-
1 (PD
-
L1 and PD
-
L2) are constitutively expressed or can be induced in various tumors 
[
12
-
15
].  
Binding of either PD
-
[ADDRESS_929296] notably on vascular endothelium, whereas PD
-
L2 protein 
is only detectably expressed on antigen
-
presenting cells found in lymphoid tissue or 
chronic inflammatory environments.  PD
-
L2 is 
thought to control immune T
-
cell 
activation in lymphoid organs, whereas PD
-
L1 serves to dampen unwarranted T
-
cell 
function in peripheral tissues [
50
].  Although healthy organs express little (if any) PD
-
L1, a variety of cancers were demonstrated to express
 
abundant levels of this T
-
cell 
inhibitor.  
High expression of PD
-
L1 on tumor cells (and to a lesser extent of PD
-
L2) 
has been found to correlate with poor prognosis and survival in various cancer types, 
including renal cell carcinoma (RCC) [
16
], pancreati
c carcinoma [
17
], hepatocellular 
carcinoma [
18
], ovarian carcinoma [
19
] and non
-
small cell lung cancer (NSCLC) [
28
].  
Furthermore, PD
-
1 has been suggested to regulate tumor
-
specific T
-
cell expansion in 
patients with malignant MEL [
20
]. 
The observed correla
tion of clinical prognosis with 
PD
-
L
1
 
expression in multiple cancers suggests that the PD
-
1/PD
-
L1 pathway plays a 
critical role in tumor immune evasion and should be considered as an attractive target 
for therapeutic intervention.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
13
 
2.3
 
Preclinical and Clinical Trial Data
 
 
Refer to the Investigator’s Brochure [IB] for Preclinical and Clinical Data
 
 
2.
4
 
Rationale
 
 
Blockade of immune checkpoints such as 
cytotoxic T
-
lymphocyte 
antigen
-
4 (
CTLA
-
4) and 
programmed death
-
1 (
PD
-
1) is showing promise in patients with cancer.  CTLA
-
[ADDRESS_929297] PD
-
1 and is showing activity in multiple 
tumor types including melanoma and non
-
small cell lung cancer (NSCLC).  Previ
ously, 
activity of a different 
PD
-
1 blocking antibody, BMS
-
936558, a fully humanized 
monoclonal  IgG4 antibody, also showed activity in melanoma, NSCLC, and a 
complete response in a single patient with colorectal cancer
 
[
28
, 
51
]
.  
 
 
As with all targeted th
erapi[INVESTIGATOR_014], we expect a subset of patients will respond to 
immunotherapy and there may be genetic determinants that define an ‘immune 
responsive’ phenotype.  A cancer genomics perspective may provide insight as to why 
patients with melanoma and NSCLC, and
 
per
haps other tumor types, respond to these 
therapi[INVESTIGATOR_014]. The average number of somatic mutations in human cancer varies widely 
(
Table 1
)
 
[
52
]
. Three factors are known to be associated with high somatic mutation 
burdens:  exposure to environmental carcinogens (e
.g. UV radiation and tobacco)
 
[
53
, 
54
]
; repair defects (e.g., mismatch repair gene inactivation)
 
[
55
]
; or exposures to 
mutagenic therapi[INVESTIGATOR_014] (e.g., alkylating agents)
 
[
56
]
.  Melanomas and NSCLC are known 
to have high burdens of somatic mutations. We 
therefore hypothesize that there will be 
a correlation between the number of somatic mutations in individual tumors and the 
response to immune checkpoint inhibitors since each protein
‐
coding mutation has the 
potential to serve as a novel antigen for an imm
une response. If this hypothesis is 
correct, it would suggest that immune checkpoint inhibitors might work best in tumors 
with 
exceptionally 
high mutation burdens
 
(>500 somatic mutations per exome)
.  
Furthermore, tumors deficient in mismatch repair
, as wel
l as other genetic alterations 
consistent with a mutator phenotype such as POLD1, and POLE mutations,
 
may be 
particularly susceptible to immunotherapy as this phenotype results in ongoing 
accumulation of mutations at a high frequency.  
 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
14
 
 
MSI tumors are 
deficient in DNA mismatch repair which leads to
 
a high rate of 
spontaneous mutations and the potential for the expression of neo
-
antigens.  
Furthermore, similar to melanoma, MSI positive colon cancers, there is often 
prominent lymphocyte infiltration
 
[
3
, 
4
]
.  This is another clue that this subset of tumors 
may have baseline tumor infiltrating lymphocytes that can be harnessed with immune 
checkpoint blockade.  Interestingly, the colorectal patient with the complete response 
is known to have an MSI positive t
umor
 
[
57
]
.  This study aims to 
evaluate 
MSI as a 
predictor of response to anti
-
PD
-
1 blockade with MK
-
3475.
 
 
Recent prospective studies looking at mutational burden (i.e. MSI) and PD
-
L1 staining 
have shown a positive correlation between these biomarkers and
 
clinical 
response.
 
 
Retrospectively, several candidate biomarkers appear promising including 
mutational burden in non
-
MSI tumors. Mechanistically, we believe that a tumor with 
high degree of ‘foreignness’ will trigger a potent anti
-
tumor immune response.
 
 
A 
tumor will look foreign to the host immune system if they have a very high mutational 
burden or hypothetically (yet to be proven) if they harbor a virus or express an 
embryonic protein.
 
 
The functional consequence of a highly foreign tumor is a 
lymphocy
tic infiltrate and high IFN
-
γ levels.
 
 
As a mechanism of immune evasion a 
number of immune checkpoints (i.e.PD
-
1) are upregulated. Since the functional 
consequence of tumor foreignness is lymphocytic infiltration of the tumor, we propose 
that this may be a
 
highly sensitive predictive marker of response to checkpoint 
blockade.
 
 
3.
 
PATIENT SELECTION
 
 
3.1
 
Eligibility Criteria
 
 
3.1.1
 
Cohort A:  
Patients with histologically proven met
astatic or locally advanced 
MSI 
colorectal
 
adenocarcinoma
.  
 
 
3.1.2
 
Cohort B:  
Patients with histologically proven metastatic or locally advanced 
microsatellite stable (MSS) colorectal 
adenocarcinoma
.
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
15
 
3.1.3 
 
Cohort C: 
Patients with histologically proven metastatic or locally advanced
 
non
-
colorectal 
MSI 
solid tumor malignancies
.
 
 
3.1
.4
 
Cohort D: Patients with histologically proven metastatic or locally advanced 
solid tumor malignancies that are microsatellite stable with a documented 
mutation burden level measured at 
>
 
2
0 mutations per megabase pairs (MB).
 
 
 
3.1.
[ADDRESS_929298] a bio
psy at baseline and on treatment if the lesion 
can be biopsied with 
acceptable clinical risk (as judged by [CONTACT_093])
.
 
 
3.1.
7
 
Patients w
ith colon cancer 
(Cohort A
 
and B
) 
must have received at least 2 prior 
cancer therapy regimens.  Patients with 
other cancer types
 
(Cohort C)
 
must have 
received
 
at
 
least [ADDRESS_929299] progressive 
disease on study entry.
 
 
3.1.
8
 
Age 
>
18 years.  
 
 
3.1.
9
 
ECOG performance status 
0
-
1
 
(
Appendix A
).
 
 
3.1.
[ADDRESS_929300] normal organ and marrow function as defined below:
 
 

 
A
bsolute neutrophil count
 
 
>
1,
0
00
/mcL
 

 
P
latelets
 
 
 
 
 
 
 
>
90 x 10
3
/uL
 

 
Hemoglobin 
 
 
 
 
 
>
9
.0 g/dL
 

 
T
otal bilirubin
 
 
 
 
 
<
1.5x ULN 
(patient
s
 
with diagnosed 
Gilbert’s Syndrome 
will not be excluded if 
their
 
direct bilirubin 
is within normal 
institutional limits
, 10X ULN if hepatic 
metastases
)
 

 
AST(SGOT)/ALT(SGPT)
 
 
<
3x 
ULN 
(
10X ULN if hepatic 
metastases
)
 

 
C
reatinine
 
 
 
 
 
 

[ADDRESS_929301] be 
negative for the patient to be eligible.
 
 
3.1.
1
3
 
Female patients enrolled in the study, who are not free from menses for >[ADDRESS_929302] hysterectomy / oophorectomy, or surgically sterilized, must be willing to 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929303] dose of study therapy.  Approved contraceptive methods include for 
example; intra uterine device, diaphragm with sp
ermicide, cervical cap with 
spermicide, male condoms, female condoms with spermicide, or oral 
contraceptives.  Spermicides alone are not an acceptable method of 
contraception.
 
Male patients must agree to use an adequate method of contraception starting 
wit
h the first dose of study drug through 
[ADDRESS_929304] dose of study 
therapy.
 
 
3.1.
1
4
 
Ability to understand and the willingness to sign a written informed consent 
document.
 
 
3.2
 
Exclusion Criteria
 
 
3.2.
1
 
Has known active central nervous system (CNS) metastases and/or 
carcinomatous meningitis.  Subjects with previously treated brain metastases 
may participate provided they are stable (without evidence of progression by 
[CONTACT_685585]), have no evidence of new or 
enlarging brain metastases, and are not using steroids for at least 
[ADDRESS_929305] had surgery within 4 weeks of dosing of investigational 
agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus 
block, and biliary stent placement
.
 
 
3.2.
[ADDRESS_929306] received any of the following concomitant therapy: IL
-
2, 
interferon or other non
-
study 
immunotherapy regimens; immunosuppressive 
agents; other investigational therapi[INVESTIGATOR_014]; or chronic use of systemic 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
17
corticosteroids (used in the management of cancer or non
-
cancer
-
related 
illnesses)
 
within [ADDRESS_929307] dose
.
 
Note: Systemic steroid thera
py 
allowed for subjects 
with
 
primary brain tumors
 
as long as 
≤ dexamethasone [ADDRESS_929308] received 
a live
 
vaccine 
within
 
4 weeks
 
prior to or after any 
dose of 
MK
-
3475
.
 
 
 
Note: Seasonal influenza vaccines for 
injection are generally inactivated flu 
vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu
-
Mist®) are live attenuated vaccines, and are not allowed.
 
 
3.2.
9
 
Patients receiving g
rowth factors including, but not limited to, granulocyte
-
colony stimulating factor (G
-
CSF), granulocyte macrophage
-
colony 
stimulating factor (GM
-
CSF), erythropoietin, etc. within 
2 weeks
 
of study drug 
administration. Use of such agents while on study is also prohibited.
 
Prior use 
of growth factors should be doc
umented in the patient’s medical history.
 
 
3.2.
1
0
 
Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, symptomatic congestive heart failure, unstable angina pectoris, 
cardiac arrhythmia, or psychiatric 
illness/social situations that would limit 
compliance with study requirements.
 
 
3.2.
[ADDRESS_929309] 
2 years (i.e. with use of disease modifying agents, corticosteroids or 
immunosuppressive 
drugs). Replacement therapy (
e.g.
 
thyroxine, insulin, or 
physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_12978], etc.) is not considered a form of systemic treatment.
 
 
3.2.[ADDRESS_929310] 
dose of trial treatment.
 
 
3.2.
1
3
 
Presence of any tissue or organ allograft, regardless of need for 
immunosuppression, including corneal allograft. 
In
stances where loss of the 
graft is not a clinical concern (such as dental bone grafts or skin grafts placed 
only to promote skin growth) can be approved by [CONTACT_36476].
 
Patients 
with a history of allogeneic 
hematopoietic
 
stem cell transplant will be
 
excluded.
 
 
3.2.14 
 
Patients with
 
a known history of Human Immunodeficiency Virus (HIV) (HIV 
1/2 antibodies).
 
 
3.2.
1
5
 
Patients with a
 
known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C 
(e.g., HCV RNA [qualitative] is detected)
.
 
 
3.2.
1
6
 
Patients with 
evidence of interstitial lung disease
.
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
18
3.2.
1
7
 
Patients with a pulse oximetry of <92% on room air
.
 
 
3.2.
1
8
 
Patients on supplemental home oxygen
.
 
 
3.2.
1
9
 
Patient is, at the time of signing informed consent, a regular user (including 
“recreational use”) of any illicit drugs or had a recent history (within the last 
year) of substance abuse (including alcohol).
 
 
3.2.
[ADDRESS_929311] tissue for MSI testing. 
The prescreening 
consent can be obtained over the phone.  
A copy of the consent will be faxed to the site 
and the original will be mailed.  
MS
I status will be 
performed
 
locally by [CONTACT_685586] (IHC) or
 
PCR
 
based
 
tests
 
for eligibility
. 
 
 
Evaluable patients will be confirmed 
using
 
the MSI Analysis System from Promega
.
 
Th
is
 
test
 
will
 
determine 
MSI status through the 
insertion
 
or deletion of repeating units 
in the five nearly monomorphic mononucleotide repeat markers (BAT
-
25, BAT
-
26, 
MON0
-
27, NR
-
21 and NR
-
24). At least 2 MSI loci are required 
to be evaluable 
in 
Cohort
s
 
A and C.
 
Patients may be 
assigned to a new cohort 
and/or 
re
placed 
based on 
the Promega test results.
 
With amendment 9, the decision was made to not require 
retesting with Promega if MSI status is confirmed by [CONTACT_270212].
 
 
The MSI Analysis System (Promega), Version 1.2, is a fluorescent multiplex PCR
-
based me
thod 
used to 
detect microsatellite instability (MSI), a form of genomic 
instability. This instability is due to insertion or deletion of repeating units during DNA 
replication and failure of the mismatch repair system (MMR) to correct these errors. 
MSI analysis typi[INVESTIGATOR_685570], which may be MMR
-
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
19
deficient, and normal tissue samples. New alleles in the abnormal sample not found in 
the corresponding normal
 
sample indicate the presence of MSI. 
 
 
The MSI Analysis System, Version 1.2, includes fluorescently labeled primers (marker 
panel) for co
-
amplification of seven markers for analysis of the MSI
-
high (MSI
-
H) 
phenotype, including five nearly monomorphic 
mononucleotide repeat markers (BAT
-
25, BAT
-
26, MON0
-
27, NR
-
21 and NR
-
24) and two highly polymorphic 
pentanucleotide repeat markers (Penta C and Penta D). Amplified fragments are 
detected using an ABI PRISM® 310, 3100, 3100
-
Avant, 3130 or 3130xl Genetic 
Ana
lyzer after spectral calibration.
 
GeneMapper® 4.0 software
 
will be used for
 
data 
analysis 
and assignment of genotype
.
 
 
For cohort D, any testing performed in a CLIA
-
certified laboratory for 
m
ismatch repair 
deficiency 
(
MRD
)
 
or MSI using IHC, PCR or 
next gen
eration sequencing (
NGS
)
 
approach can be used to exclude the presence of MRD or MSI.
 
 
3.[ADDRESS_929312] to determine mutational 
burden is through whole genome or exome sequencing.  A surrogate to exome or whole 
genome sequencing is targeted sequencing of a large fraction of the exome to determine 
total mutational burden.  Mutations can occur as si
lent mutations (synonymous) or 
missense mutations (non
-
synonymous).  We would like to treat tumors that harbor 
>
 
[ADDRESS_929313] for eligibility
. 
Evaluable patients will be confirmed 
us
ing
 
Foundation 
Medicine
 
(http://foundationone.com/) 
targeted sequencing panel that 
reports mutation burden
.  Please see 
Appendix B
 
for information regarding this test.
 
 
4.
 
REGISTRATION PROCEDURES
 
 
4.[ADDRESS_929314]
 
the 
Protocol Chair
 
at 
 
to verify 
ongoing study enrollment
.  
The fax cover sheet, Registration Form, and Eligibility 
Worksheet 
will be supplied to each participating site
.
 
 
If a patient does not receive protocol therapy following reg
istration, the patient’s 
registration on the study may be canceled.  The Study Coordinator should be notified 
of cancellations as soon as possible.
 
 
4.2
 
Registration Process
 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
20
To register a patient, the following docume
nts should be 
completed and sent to 
the 
Lead Study Coordinator
 
at the Coordinating Center
 
at 
:
 

 
Fax cover sheet
 

 
Registration Form
 

 
Signed patient consent form
 

 
HIPAA authorization form
 

 
Eligibility Screening Checklist
 

 
Copy of required screening tests
 
and scans
 
 
The 
Research Nurse or Study Coordinator 
at the participating site will then call
 
or
 
e
-
mail
 
the 
Lead Study Coordinator
 
at the 
 
Coordinating Center 
to verify eligibility.  To 
complete the registration process, the 
Coordinating Center 
Lead 
Study 
Coordinator 
will
:
 

 
Assign a patient study number
 

 
Register the patient on the study
 

 
Fax or e
-
mail the patient study number to the participating site
 

 
Call
 
or e
-
mail
 
the research nurse or data manager at the participating site and 
verbally confirm registration.
 
 
 
5
.
 
TREATMENT 
PLAN
 
 
5
.1
 
Agent Administration
 
 
Treatment will be administered on an outpatient basis.  Appropriate dose modifications 
are described in 
Section 6
.  No investigational or commercial agents or therapi[INVESTIGATOR_685571]'s 
malignancy
.
 
 
REGIMEN DESCRIPTION
 
Agent
 
Premedications; 
Precautions
 
Dose
 
Route
 
Schedule
 
Cycle 
Length
 
MK
-
3475
 
No prophylactic 
pre
-
medication will be given 
unless indicated by [CONTACT_685587] 5.2.1
.
 
10 
mg/kg
 
(Cohorts 
A, B, and 
C)
 
 
200 mg 
(Cohort 
D)
 
IV over 
30 
minutes
 
Day
 
1
 
14 days
 
(Cohort
s A, B, 
and C)
 
 
21 days 
(Cohort 
D)
 
 
MK
-
3475 will be administered 
per the package insert
. 
 
The pharmacists will prepare the MK
-
3475 
per the
 
package insert.
 
 
5
.2
 
General Concomitant Medication and 
Supportive Care Guidelines
 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929315] of fever, chills/rigor, nausea, pruritus, 
angioedema, hypotension, headache, bronchospasm, urticaria, rash, vomiting, myalgia, 
dizziness or hypertension.  Severe reac
tions may include acute respi[INVESTIGATOR_13086], myocardial infarction, ventricular fibrillation, and cardiogenic shock.  
Patients should be closely monitored for such reactions.  Guidelines for patients who 
experience an infusion related or allergic
 
reaction during or after infusion with MK
-
3475 are shown below.
 
 
Guidance on Infusion and Hypersensitivity Reactions:
 
 
NCI CTCAE Grade
 
Treatment
 
Premedication at subsequent 
dosing
 
Grade 1
 
Mild reaction; infusion interruption 
not indicated; intervention 
not 
indicated
 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opi[INVESTIGATOR_871].
 
None
 
Grade 2
 
Requires infusion interruption but 
responds promptly to symptomatic 
treatment (e.g., 
antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated 
for < =24 hrs
 
Stop Infusion and monitor symptoms.
 
Additional appropriate medical therapy may 
include but is not limited to:
 
IV fluids
 
Antihistamines
 
NSAIDS
 
Acetaminophen
 
Narcotics
 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opi[INVESTIGATOR_871].
 
If symptoms resolve within one hour of stoppi[INVESTIGATOR_108607], the infusion may be restarted at 
50% of the 
original infusion rate (e.g., from 100 
mL/hr to 50 mL/hr).  Otherwise dosing will be 
held until symptoms resolve and the subject 
should be premedicated for the next scheduled 
dose.
 
Subjects who develop Grade [ADDRESS_929316] may be premedicated 1.5h 
(± 30 minutes) prior to infusion of 
pembrolizumab (MK
-
3475) with:
 
 
Diphenhydramine 50 mg po (or 
equivalent dose of antihistamine).
 
 
Acetaminophen 500
-
1000 mg po 
(or equivalent dose of antipyretic).
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
22
NCI CTCAE Grade
 
Treatment
 
Premedication at subsequent 
dosing
 
Grades 3 or 4
 
Grade 3:
 
Prolonged (i.e., not rapi[INVESTIGATOR_77984]/or 
brief interruption of infusion); 
recurrence of symptoms following 
initial improvement; hospi[INVESTIGATOR_685572] 
(e.g., renal impairment, pulmonary 
infiltrates)
 
Grade 4:
 
Life
-
threatening; pressor or 
ventilatory support indicated
 
Stop Infusion.
 
Additional appropriate medical therapy may 
include but is not limited to:
 
IV fluids
 
Antihistamines
 
NSAIDS
 
Acetaminophen
 
Narcotics
 
Oxygen
 
Pressors
 
Corticosteroids
 
Epi[INVESTIGATOR_685573].
 
Hospi[INVESTIGATOR_685574].
 
Subject is permanently discontinued from 
further trial treatment administration.
 
No subsequent dosing
 
Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of dr
ug 
administration.
 
 
 
5.2.
2
 
Immune
-
Related Adverse Events (IRAEs) 
 
 
Blocking 
PD
-
1
 
function may permit the emergence of auto
-
reactive T cells and 
resultant clinical autoimmunity. Rash
/pruritis
, diarrhea/colitis, 
pneumonitis, 
hepatitis
,
 
and 
hypothyroidism
 
were drug
-
related, presumptive autoimmune events, now termed 
IRAEs
, noted in previous 
BMS 936558
 
studies.
 
 
 
For the purposes of this study, an IRAE is defined as an AE of unknown etiology, 
associated with drug exposure and is consistent with an immune phe
nomenon. Efforts 
should be made to rule out neoplastic, infectious, metabolic, toxin or other etiologic 
causes prior to labeling an AE an IRAE. Serological, immunological, and histological 
(biopsy) data should be used to support the diagnosis of an immune
-
mediated toxicity. 
Suspected IRAEs must be documented on an AE or SAE CRF.
 
Identification
 
and 
treatment of IRAEs can be found in 
Section 6.[ADDRESS_929317] (ECI) within 24 
hours
 
to the 
IND 
Sponsor and [COMPANY_006] Global Safety
 
even if no Serious Adverse Event Criteria are met.
 
 
5.2.3 Prohibited Medications
 
 
The following therapi[INVESTIGATOR_685575] (if administered, 
the subject may be removed from the study):
 
 
•
 
Any non
-
study anticancer chemotherapy or immunotherapy (approved or 
investigational)
 
•
 
Filgrastim (Neupogen® or G
-
CSF) or sargramostim
 
(Leukine® or GM
-
CSF)
 
•
 
Live 
vaccines (examples of live vaccines include, but are not limited to: measles, 
mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid [oral] vaccine). 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
23
Seasonal influenza vaccines for injection are generally killed virus vaccines and are 
allowed
. However, intranasal influenza vaccines (e.g. Flu
-
Mist
®
) are live attenuated 
vaccines, and are not allowed.
 
•
 
Systemic glucocorticoids for any purpose other than to modulate symptoms from an 
event of clinical interest of suspected immunologic etiology. The 
use of physiologic 
doses of corticosteroids may be approved after consultation with the 
IND 
Sponsor.
 
 
Note: Inhaled steroids for management of asthma are permitted.
 
 
Note: Use of prophylactic corticosteroids to avoid allergic reactions (e.g., to IV 
contrac
t dye) is permitted.
 
 
Note: Physiologic doses of corticosteroids for adrenal insufficiency are permitted.
 
 
5.3
 
Dosing Criteria
 
 
Dosing will be delayed for the following laboratory criteria
: 
 
 

 
AST, ALT > 
[ADDRESS_929318] 
(
10X ULN if hepatic metastases
)
 

 
Total bilirub
in >1.[ADDRESS_929319] 
 
(patient
s
 
with diagnosed Gilbert’s Syndrome
, 
direct 
bilirubin 
should be
 
within normal institutional limits
, 
10X ULN if hepatic 
metastases
)
 

 
Hemoglobin < 8 g/dL
 

 
ANC < 1000/uL 
 

 
Platelets < 80 x 10
3
/uL
 
 
5.4
 
Definition of an Overdose for t
his 
Protocol
 
 
Overdose is defined as:
 
The patient has taken (accidentally or intentionally) a dose exceeding the dose 
prescribed in the protocol by 20%.
 
No specific information is available on the treatment 
of overdose of MK
-
3475. In the event of overdose, MK
-
[ADDRESS_929320] should be observed closely for signs of toxicity.  Appropriate supportive 
treatment should be provided if clinically indicated.
 
 
If an adverse experience(s) is associated with (“results from”) the overdose of tes
t drug 
or vaccine, the adverse experience(s) is reported as a serious adverse experience, even 
if no other criteria for serious are met.
 
If a dose of test drug or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical 
symptoms or abnormal laboratory results, the overdose 
is reported as a non
-
serious Event of Clinical Interest (ECI), using the terminology 
“accidental or intentional overdose without adverse effect.”
 
All reports of overdose with and without an adverse expe
rience must be reported within 
24 hours to 
the Sponsor and [COMPANY_006] Global Safety.  [COMPANY_006] Global Safety (GS) contact 
[CONTACT_658907] 7.5.1
.
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929321]
-
feeding women may be enrolled if they are considered highly unlikely to 
conceiv
e.  Highly unlikely to conceive is defined as 1) surgically sterilized, or 2) 
postmenopausal (a woman who is 
≥45 years of age and has not had menses for greater 
than 2 years will be considered postmenopausal), or 3) 
amenorrheaic for <[ADDRESS_929322]
erectomy and oophorectomy and with a documented FSH value in the 
postmenopausal range, or 
4) not heterosexually active for the duration of the study, or 
5) heterosexually active and willing to use 2 methods of birth control (which is also 
required 
for the 
female partners of male patients). The [ADDRESS_929323] 
dose of study drug
.
 
 
The following are considered adequate barrier methods of contraception: diaphragm,
 
condom (by [CONTACT_3969]), copper intrauterine device, sponge, or spermicide.  
Appropriate hormonal contraceptives will include any registered and marketed 
contraceptive agent that contains an estrogen and/or a progestational agent (including 
oral, subcutan
eous, intrauterine, or intramuscular agents).
 
 
Patients should be informed that taking the study medication may involve unknown 
risks to the fetus (unborn baby) if pregnancy were to occur during the study.  In order 
to participate in the study they 
must ad
here
 
to the contraception requirement (described 
above) for the duration of
 
the study.  
If there is any question that a patient will not 
reliably comply with the requirements for contraception, that patient should not be 
entered into the study.
 
 
5.
[ADDRESS_929324] adverse effects on a fetus; therefore, women with a positive 
pregnancy test at screening will not be eligible for enrollment.  If a patient inadvertently 
becomes pregnant while on treatment with MK
-
3475, the patient will imme
diately be 
removed from the study.  The site will contact [CONTACT_270218]’s status until the pregnancy has been completed or terminated.  The outcome 
of the pregnancy will be reported to the 
Sponsor 
and to [COMPANY_006] Global
 
Safety 
without 
delay
.  The outcome must be reported
 
to the S
ponsor
 
within 24 hours 
and to [COMPANY_006] 
Global Safety 
if the outcome is a serious adverse experience (e.g., death, abortion, 
congenital anomaly, or other disabling or life
-
threatening complication to
 
the mother 
or newborn).  If a male patient’s partner becomes pregnant on study the pregnancy must 
be reported to the 
Sponsor 
and to [COMPANY_006]
 
Global Safety
 
as described in 
Section 7.5.1
.  
The study Investigator will make every effort to obtain permission to f
ollow the 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929325] be discontinued from the trial for the following reason:
 
 
•
 
The 
subject or legal representative (such as a parent or legal guardian) 
withdraws consent.
 
A subject must be 
taken off study
 
(but may continue to be monitored in the post
-
treatment follow
-
up portion of the trial
 
per 
Section 5.9
) for any of the following 
reaso
ns:
 
 

 
The subject or legal representative (such as a parent or legal guardian) 
withdraws consent for treatment
 

 
Disease progression after 
7 
months
 
of therapy.  Approval for continuation 
from the IND sponsor may be obtained if the patient is thought to be 
clinically benefiting. 
 
 

 
Intercurrent illness that prevents further administration of treatment,
 
 

 
Unacceptable adverse event(s)
 
(see 
section 5.
10
.2
)
,
 
 

 
Need for >2 dose delays due to the same toxicity as per the dose 
delay
 
guidelines (see 
S
ection 
6.2
)
 
 

 
Patient withdraw
s consent,
 
 

 
If in the opi[INVESTIGATOR_689], a change or temporal or permanent 
discontinuation of therapy would be in the best in
terest of the patient.  The 
IND 
S
ponsor
 
and [COMPANY_006] 
should be included in this decision,
 
 

 
Noncompliance with trial treatment or procedure requirements,
 
 

 
Patient is lost to follow
-
up, or
 
 

 
Patient becomes pregnant
.
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929326] be 
taken off treatment
 
(but continue to be monitored in the post
-
treatment 
follow
-
up portion of the trial
 
per 
Section 5.
7.1
) for the following reason:
 
 

 
Completed 24 months of treatment with MK
-
3475
 
(see 
Section 5.
7
)
 
 
Note: [ADDRESS_929327] dose. 
 
  
 
5.
7
 
Off Tr
eatment Evaluation
 
and Re
treatment Criteria
 
 
5.
7
.1 Off Treatment Evaluation
 
 
If
 
a patient is discontinued from MK
-
3475 after completion of 24 months of treatment
 
(or 
the patient 
has 
discontinued MK
-
3475 after 
an investigator determined confirmed 
CR
)
, a mandatory Off Treatment Evaluation should be performed 30 days (+/
-
 
7
 
days) 
after the last infusion of 
MK
-
3475
 
as described in 
Section 10
. 
The
 
assessment of AEs 
and
 
medications can be made either as part of a clinical visit or over the phone. 
P
atients 
should continue to be monitored by [CONTACT_70719]
, clinical labs,
 
and tumor 
marker(s) 
approximately every 12 weeks for 3 years
 
(
timing calculated from
 
the first 
dos
e of MK
-
3475
).
 
After [ADDRESS_929328]
 
as described in 
Section 10
.
 
Patients 
will 
also 
continue to 
be monitored for 
new drug
-
related AEs 
and
 
the resolution of ongoing 
drug
-
related 
AEs to 
≤ Grade 1. 
SAEs that occur within [ADDRESS_929329],
 
should also be followed and recorded.
 
 
5.
7
.2 Retreatmen
t with MK
-
3475
 
 
Patients who stop MK
-
3475 with SD or better may be eligible for up to one year of 
additional MK
-
3475 therapy if they progress after stoppi[INVESTIGATOR_270196]
-
3745
 
and they meet 
the following criteria:
 
 
 
EITHER
 
 
o
 
Stopped initial treatment with MK
-
[ADDRESS_929330] 1.1
 

 
Was treated for at least 24 weeks with MK
-
3475 before discontinuing 
therapy
 

 
Received at least two treatments with MK
-
[ADDRESS_929331] had SD, PR or CR and stopped MK
-
3475 treatment after 24 months of 
study therapy for reasons other than disease progression or intolerability
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
27
 
AND
 
 

 
Experienced an investigator
-
determined confirmed radiographic disease 
progression after stoppi[INVESTIGATOR_685576]
r initial treatment with MK
-
3475
 

 
Did not receive any anti
-
cancer treatment since the last dose of MK
-
3475
 

 
Have a performance status of 0 or 1 on the ECOG Performance Scale
 

 
Demonstrate adequate organ function as detailed in 
Section 5.3
 

 
Female subject of 
childbearing potential should have a negative urine or serum 
pregnancy test within 72 hours prior to receiving retreatment with study 
medication.
 

 
Female subjects of childbearing potential should be willing to use [ADDRESS_929332] dose of study medication 
(
Section 5.5.1
). 
 

 
Male subjects should agree to use an adequate method of contraception starting 
with the first dose of stu
dy therapy through [ADDRESS_929333] dose of study 
therapy.
 

 
Does not have a history or current evidence of any condition, therapy, or laboratory 
abnormality that might interfere with the subject’s participation for the full duration 
of the trial or i
s not in the best interest of the subject to participate, in the opi[INVESTIGATOR_99912].
 
Subjects who restart treatment should resume at the same dose and cycle interval which 
they were receiving prior to discontinuation. Study visit requirem
ents are outlined in 
the Study Calendar (
S
ection 10.0
).
 
 
5.8
 
Off Study/
Safety Follow
-
up Visit
 
 
After a patient is discontinued from MK
-
3475
 
(patient is not eligible for retreatment 
per 
Section 5.7
)
, a mandatory Off Study/Safety Follow
-
Up Visit should be pe
rformed 
approximately [ADDRESS_929334] infusion of study medication (or within [ADDRESS_929335]). Procedures 
and assessments performed at this visit and beyond should follow the respecti
ve 
guidelines described in 
S
ection 10.0
 
as appropriate.  The patient will be monitored for 
adverse events up to the mandatory Off Study/Safety Follow
-
Up Visit or to resolution 
of toxicity to Grade [ADDRESS_929336].
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929337] come off study 
without documented disease progression
 
(or to 
receive the FDA approved do
se of pembrolizumab for microsatellite instability
-
high 
cancer)
, should continue to be monitored for disease status by [CONTACT_70719].  
Disease monitoring should continue to be assessed 
approximately 
every 12 weeks 
for 
3 years
, followed by 
[CONTACT_140992]
y every 6 months after 3 years
 
and annually after 5 
years
 
(timing calculated 
from the first dose of MK
-
3475
) 
until, 1) start 
of a new 
antineoplastic therapy
 
(
i
nformation of the new cancer therapy will be collected), 
2
) 
documented disease progression, 
3) st
udy closure, 
or 4) until death, whichever occurs 
first.
 
 
Patients who 
are off study
 
should be contact[CONTACT_685584] 3 
years
, followed by 
[CONTACT_605507] 6 months after 3 years
 
and annually after 5 
years
 
(timing calculated from 
the first dose of MK
-
3475
)
 
to monitor overall survival.  
Information of other cancer therapi[INVESTIGATOR_685569].
 
 
SAEs that occur within [ADDRESS_929338]
 
criteri
a (irRC). 
Subjects that meet the 
above criteria and continue on study therapy must discontinue
 
MK
-
3475 
if 
there are no 
signs of disease stabilization by
 
7 
months using irRC
 
(or by [CONTACT_685588] 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
29
still pending)
.
 
Tumor assessments in the second expansion cohort 
and Cohort D 
will 
be evaluated by [CONTACT_393] 1.1 criteria only.
  
Approval for continuation fro
m the IND 
sponsor may be obtained if the patient is thought to be clinically benefiting. 
 
 
5.
10
.2 IRAEs
 
 
Permanent discontinuation of MK
-
3475 should be considered for any of the following:
 
1.
 
Severe or life
-
threatening 
related 
adverse reactions, including,
 
but not limited to, 
any of the following (
IND 
Sponsor and [COMPANY_006] 
must be notified in the event of these 
AEs, and final decision regarding treatment will be made after a discussion):
 

 
Grade 
3
-
4 toxicity (non
-
hematologic or hematologic)
.  Grade 3 toxicit
ies
 
m
ay 
be able to be re
-
dosed on a case by [CONTACT_685589] 
S
ponsor
 
and [COMPANY_006]
.
 

 
Diarrhea with abdominal pain, fever, ileus, or peritoneal signs; increase in stool 
frequency (7 or more over baseline), stool incontinence, need for intravenous 
hydration for more than 24 hours, gastrointestinal hemorrhage, and 
gastrointestinal perforation
 

 
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times 
upper limit of normal
 

 
Total serum bilirubin >3 times upper limit of normal
 

 
Steven
-
Jo
hnson syndrome, toxic epi[INVESTIGATOR_194], or rash complicated by 
[CONTACT_658912], bullous or hemorrhagic 
manifestations
 

 
Severe (i.e., CTCAE Grade 3 or 4) motor or sensory neuropathy
 

 
Any grade
 
Guillain
-
Barré syndrome, or myast
henia gravis or other neurologic 
symptoms that impact activity of daily living
 

 
Severe immune
-
mediated reactions involving any other organs (e.g., nephritis, 
pneumonitis, pancreatitis, non
-
infectious myocarditis)
 

 
Immune
-
mediated ocular disease that is unres
ponsive to topi[INVESTIGATOR_270197]
 

 
Grade 
3 or 
4 infusion reaction
 
2.
 
Inability to reduce corticosteroid dose for immune
-
related adverse reactions to 
≤10 
mg prednisone or equivalent per day
 
If any of the above
 
events occur, the investigator should discuss with 
the 
IND 
S
ponsor and [COMPANY_006]
 
to make a decision on discontinuation of MK
-
3475 study 
treatment.  
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
30
 
In case toxicity does not resolve or improve to 
≤ Grade [ADDRESS_929339] occurrence of the same toxicity which would require 
dosing delay, study therapy will be discontinued permanently.
 
 
6
.
 
DOSING DELAYS/DOSE MODIFICATIONS
 
 
6.1 
 
Dose Modifications
 
 
 
 
 
 
Do
se reduction or dose increase of MK
-
3475 will not be permitted in individual 
patients
.
 
 
6.2 
 
Dosing Delays
 
 
MK
-
3475 will be withheld for 
the following 
drug
-
related 
toxicities and severe or life
-
threatening AEs
 
as per 
the table below:
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
31
General instructions:
 
1.
 
Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_929340] dose or corticosteroids cannot be 
reduced to 
≤[ADDRESS_929341] followed by [CONTACT_44874]. Other immunosuppressive treatment 
should be initiated if irAEs cannot be controlled by [CONTACT_13216].
 
 
Immune
-
related 
AEs
 
Toxicity grade or 
conditions 
(CTCAEv
4.0)
 
Action taken to 
pembrolizumab
 
irAE management with 
corticosteroid and/or other 
therapi[INVESTIGATOR_658877]
-
up 
 
Pneumonitis 
 
Grade 2
 
Withhold 
 

 
Administer corticosteroids (initial 
dose of 1
-
2 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]
 
 

 
Monitor
 
participants for signs and 
symptoms of pneumonitis
 

 
Evaluate participants with suspected 
pneumonitis with radiographic imaging and 
initiate corticosteroid treatment
 

 
Add prophylactic antibiotics for 
opportunistic infections
 
Grade 3 or 4, or 
recurrent 
Grade 2
 
Permanently 
discontinue
 
Diarrhea / Colitis 
 
Grade 2 or 3
 
Withhold
 

 
Administer corticosteroids (initial 
dose of 1
-
2 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]
 
 

 
Monitor participants for signs and symptoms 
of enterocolitis (ie, diarrhea, 
abdominal 
pain, blood or mucus in stool with or 
without fever) and of bowel perforation 
(ie,
 
peritoneal signs and ileus).
 

 
Participants with 
≥ Grade 2 diarrhea 
suspecting colitis should consider GI 
consultation and performing endoscopy to 
rule out colitis. 
 

 
Participants with diarrhea/colitis should be 
advised to drink liberal quantities of clear 
fluids.  If sufficient oral fluid intake is not 
feasible, fluid and electrolytes should be 
substituted via IV infusion.
 
Grade [ADDRESS_929342] / 
ALT 
elevation or 
Increased 
bilirubin
 
Grade 2
 
Withhold
 

 
Administer corticosteroids (initial 
dose of 0.5
-
 
1 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]
 

 
Monitor with liver function tests (consider 
weekly or more frequently until liver 
enzyme value return
ed to baseline or is 
stable
)
 
Grade 3 or 4 
 
Permanently 
discontinue
 
 

 
Administer corticosteroids (initial 
dose of 1
-
2 mg/kg prednisone or 
equivalent) followed by [CONTACT_658914] 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
32
Type 1 diabetes 
mellitus (T1DM) 
or 
Hyperglycemia
 
 
Newly onset 
T1DM or 
 
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of 

-
cell 
failure
 
Withhold
 

 
Initiate insulin replacement 
therapy for participants with 
T1DM 
 

 
Administer anti
-
hyperglycemic in 
participants with hyperglycemia 
 
 

 
Monitor participants for hyperglycemia or 
other signs and symptoms of diabetes.
 
Hypophysitis
 
Grade 2
 
Withhold
 

 
Administer corticosteroids and 
initiate hormonal replacements as 
clinically indicated.  
 
 

 
Monitor for 
signs and symptoms of 
hypophysitis (including hypopi[INVESTIGATOR_130969])
 
 
Grade 3 or 4 
 
Withhold or 
permanently 
discontinue
1
 
 
Hyperthyroidism 
 
Grade 2
 
Continue 
 

 
Treat with non
-
selective beta
-
blockers (eg, propranolol) or 
thionamides as appropriate 
 

 
Monitor for signs and symptoms of thyroid 
disorders. 
 
 
Grade 3 or 4 
 
Withhold or 
 
permanently 
discontinue
1
 
Hypothyroidism
 
Grade 2
-
4
 
Continue 
 

 
Initiate thyroid replacement 
hormones (eg, levothyroxine or 
liothyroinine) per standard of care
 

 
Monitor for signs and symptoms of thyroid 
disorders. 
 
 
Nephritis and 
Renal 
dysfunction
 
Grade 2
 
Withhold 
 

 
Administer corticosteroids 
(prednisone 1
-
2 mg/kg or 
equivalent) followed by [CONTACT_13217].
 

 
Monitor changes of renal function
 
 
Grade 3 or 4 
 
Permanently 
discontinue
 
Myocarditis
 
Grade 1 or 2
 
Withhold
 

 
Based on severity of AE 
administer corticosteroids
 

 
Ensure adequate evaluation to confirm 
etiology and/or exclude other causes
 
 
Grade 3 or 4
 
Permanently 
discontinue
 
All other 
immune
-
related 
AEs
2
 
 
Intolerable/ 
persistent Grade 2
 
Withhold
 

 
Based on type and severity of AE 
administer corticosteroids 
 

 
Ensure adequate evaluation to confirm 
etiology and/or exclude other causes
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
33
All other 
immune
-
related 
AEs
2
 
Grade 3
 
Withhold or 
discontinue based 
on the type of 
event.  Events that 
require 
discontinuation 
include and not 
limited to:  
Gu
i
llain
-
Barre 
Syndrome, 
encephalitis
 
Grade 4 or 
recurrent Grade 3 
 
Permanently 
discontinue
 
NOTE
S
: 
  
 
1
 
Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.
 
For participants with Grade 3 or 4 
immune
-
related endocrinopathy where withhold of pembrolizumab is required, pembrolizumab may be resumed when AE resolves to 
≤ Grade 
2 and is 
controlled with hormonal replacement therapy or achieved metabolic control (in 
case of T1DM).
 
[ADDRESS_929343] 
dose.
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929344] infusion, trial treatment 
should be discontinued after consultation with the 
IND 
Sponsor.  With 
IND 
Sponsor and [COMPANY_006] 
agreement, subjects with a laboratory adverse event still at Grade 2 after 12 weeks may 
continue treatment in the trial only if asymptomatic and controlled.
 
 
Dosing interruptions are permitted in the case of medical / s
urgical events or logistical reasons 
not related to study therapy (e.g., elective surgery, unrelated medical events, patient vacation, 
and/or holidays). Subjects should be placed back on study therapy within 3 weeks of the 
scheduled interruption, unless ot
herwise discussed with the 
IND 
Sponsor. The reason for 
interruption should be documented in the patient's study record.
 
 
7.
 
ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS
 
 
This study will use the descriptions and grading scales found in the revised Natio
nal Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for adverse 
event reporting that can be found at 
http://ctep.cancer.gov/proto
colDevelopment/electronic_applications/ctc.htm
.
 
 
Information about all adverse events, whether volunteered by [CONTACT_423], discovered by 
[CONTACT_424], or detected through physical examination, laboratory test or other 
means, will be collected, 
recorded, and followed as appropriate. 
 
 
All adverse events experienced by [CONTACT_641545], throughout the study, and will only be followed for 
[ADDRESS_929345] an ongoing adverse event related to the study procedures and/or 
medication(s) may continue to be periodically contact[CONTACT_426] a 
member of the study staff until 
the event is resolved or determined to be irreversible by [CONTACT_093].
 
 
Patients who experience a Grade [ADDRESS_929346] (ECI) within 24 
hours 
to the 
IND 
Sponsor and to [COMPANY_006] Global Safety
 
even if no Serious Adverse Event 
Criteria are met.
 
 
Laboratory abnormalities:
 
Laboratory abnormalities present at the screening visit will be 
recorded as pre
-
trea
tment signs and symptoms. After study treatment administration, 
all grade 
3 and 4 clinical laboratory results that represent an increase in severity from baseline will be 
reported as adverse events. A grade 1 or 2 clinical laboratory abnormality should be 
reported 
as an adverse event only if it is considered clinically significant by [CONTACT_093].
 
 
7.1
 
Definitions
 
 
7.1.1 
Adverse Event (AE)
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
35
Adverse event is defined as any undesirable sign, symptom or medical condition 
occurring after starting the study 
drug (or therapy) even if the event is not 
considered to be related to the study. An undesirable medical condition can be 
symptoms (e.g., nausea, chest pain), signs (e.g.
, 
tachycardia, enlarged liver) or 
the abnormal results of an investigation (e.g.
, 
labo
ratory findings, 
electrocardiogram). Medical conditions/diseases present before starting the study 
treatment are only considered adverse events if they worsen after starting the 
study treatment (any procedures specified in the protocol). Adverse events 
occ
urring before starting the study treatment but after signing the informed 
consent form will 
not 
be recorded. Abnormal laboratory values or test results 
constitute adverse events only if they induce clinical signs or symptoms or require 
therapy.
 
Additionall
y, expected progression of the disease being studied will not 
be recorded as an adverse event
 
 
7.1.2
 
Serious 
Adverse Event (SAE)
 
 
A serious adverse event is an undesirable sign, symptom or medical condition 
which: 
 
• Results in death 
 
• Is life threatening (defined as an event in which the subject was at risk of death 
at the time of the event; it does not refer to an event which hypothetically might 
have caused death if it were more severe) 
 
•
 
Requires inpatient hospi[INVESTIGATOR_685577] (see note below for exceptions) 
> 24 hours
 
• Results in persistent or significant disability/incapacity 
 
• 
Is a congenital anomaly/birth defect (note: reports of congenital
 
anomalies/birth defects must also be repor
ted on the Pregnancy Supplemental 
Form) 
 
• Is an important medical event (defined as a medical event(s) that may not be 
immediately life
-
threatening or result in death or hospi[INVESTIGATOR_313], based 
upon appropriate medical and scientific judgment, may jeop
ardize the subject 
or may require intervention [
e.g.
, medical, surgical] to prevent one of the other 
serious outcomes listed in the definition above.). Examples of such events 
include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not 
result in hospi[INVESTIGATOR_059].)
 
•
 
Is a new cancer (that is not a condition of the study)
 
•
 
Is associated with an overdose
 
 
Events 
not 
considered to be serious adverse events are hospi[INVESTIGATOR_314]: 
 
• Admissions as per protocol for a planned medical/surgical procedure 
or to 
facilitate a procedure
 
• Routine health assessment requiring admission for baseline/trending of health 
status
 
(
e.g.
, routine colonoscopy) 
 
• Medical/surgical admission for purpose other than remedying ill health state and 
was planned prior to entry into the study. Appropriate documentation is 
required in these cases 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
36
• Admission encountered for another life circu
mstance that carries no bearing on 
health status and requires no medical/surgical intervention (
e.g.
, lack of 
housing, economic inadequacy, care
-
giver respi[INVESTIGATOR_040], family circumstances, 
administrative).
 
 
7.1.[ADDRESS_929347] (ECI) for MK
-
[ADDRESS_929348] (ECI) and must be recorded as such on the Adverse 
Event of 
Clinical Interest Case Report Form found in 
Appendix 
C
.
 
Events of clinical interest for thi
s trial include:
 

 
an overdose of [COMPANY_006]'s prod
uct, as defined in 
Sectio
n 5.
4
, 
that is not 
associated with clinical symptoms or abnormal laboratory results. 
 

 
a
n elevated AST or ALT lab value that is greater than or equal to 3X the upper 
limit of normal 
and
 
an elevated total bilirubin lab value that is greater than or 
equal to 2X the upper limit of normal 
and
, at the same time, an alkaline 
phosphatase lab value that is less than 2X the upper limit of normal, as 
determined by [CONTACT_13149]
-
specified laborat
ory testing or unscheduled 
laboratory testing.*
 
*
Note
:  These criteria are based upon available regulatory guidance documents.  
The purpose of the criteria is to specify a threshold of abnormal hepatic tests that 
may require an additional evaluation for an
 
underlying etiology.  
 
7.2
 
Relationship
 
 
Definite
 
–
 
The AE 
is clearly related
 
to the study treatment.
 
Probable
 
–
 
The AE 
is likely related 
to the study treatment.
 
Possible
 
–
 
The AE 
may be related
 
to the study treatment.
 
 
Unlikely
 
–
 
The AE 
is doubtfully related 
to the study treatment.
 
 
 
Unrelated
 
–
 
The AE 
is clearly NOT related
 
to the study treatment
.
 
 
7.3
 
Expectedness
 
 
Unexpected adverse event:
 
An adverse event, which varies in nature, intensity or 
frequency from information on the investigational drug/agent provided in the 
Investigator’s Brochure, package insert or safety reports. Any adverse event that is not 
included in the informed consent i
s considered “unexpected”. 
An expected AE with a 
fatal outcome should be considered unexpected unless the IB specifically states that the 
AE might be associated with a fatal outcome.
 
 
Expected (known) adverse event:
 
An adverse event, which has been reporte
d in the 
Investigator’s Brochure. An adverse event is considered “expected”, only if it is 
included in the informed consent document as a risk.
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
37
7.4
 
Handling of Expedited Safety Reports
 
 
In accordance with local regulations, the 
IND 
Sponsor ([CONTACT_685598]
) will n
otify investigators 
of all SAEs that are unexpected (
i.e.
, not previously described in the Investigator 
Brochure), and definitely, probably, or possibly related to MK
-
3475. This notification 
will be in the form of an expedited safety report (ESR) that is t
o be faxed to the 
investigators and the study coordinators. Upon receiving such notices, the investigator 
must review and retain the notice with the Investigator’s Brochure and where required 
by [CONTACT_427], the investigator will submit the ESR to th
e appropriate IRB. The 
investigator and IRB will determine if the informed consent requires revision. The 
investigator should also comply with the IRB procedures for reporting any other safety 
information. 
 
 
7.5 
 
Reporting
 
 
7.
5
.1 
 
General
 
 
All adverse events (both expected and unexpected) will be captured on the 
appropriate study
-
specific case report forms (CRFs). 
 
 
In addition, all serious adverse events, regardless of causality to study drug and/or 
administration device, will be reported p
romptly to [CONTACT_685599]
 
(e
-
mail
: 
 within [ADDRESS_929349] be followed by [CONTACT_685590] r
eporting form on 
the next business day.
 
 
All serious adverse events, regardless of causality to study drug and/or 
administration will be 
forwarded to [COMPANY_006]’s Global Safety (“[COMPANY_006] GS”) group 
within 
[ADDRESS_929350]’s condition.
 
 
All SAE(s) will be followed until:
 
•
 
Resolution
 
•
 
The condition stabilizes
 
•
 
The event 
is otherwise explained
 
•
 
The subject is lost to follow
-
up
 
 
As soon as relevant information is available
, a follow
-
up SAE report will be 
submitted to the IND Sponsor and [COMPANY_006] GS.
 
 
Non
-
serious Events of Interest will be forwarded to [COMPANY_006] GS and will be handled in 
the same manner as SAEs. 
 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929351] (spontaneously reported to them), including the pregnancy of 
a male subject's female partner who has provided written consent to provide 
information regarding pregnancy, that occurs during the trial or within 
[ADDRESS_929352] be followed to the 
completion/termination of the pregnancy.  Pregnancy outcomes of spontaneous 
abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, 
intrauterine death, 
miscarriage and stillbirth must be reported as serious events 
(Important Medical Events).  If the pregnancy continues to term, the outcome 
(health of infant) must also be reported to [COMPANY_006] GS.
 
SAE reports and any other relevant safety information are to be
 
forwarded to 
[COMPANY_006] GS facsimile number:  
 
 
7.
[ADDRESS_929353] (IRB)
 
 
Participating sites will be responsible for reporting to their
 
IRB
. 
S
erious adverse 
events will be reported to the IRB per institutional
 
standards
. Upon 
receipt
, 
follow
-
up information will be given to the IRB 
(as soon as relevant information is 
available) 
per institutional standards
.
 
 
7.
5
.3 
 
Food and Drug Administration (FDA)
 
 
All reporting to the FDA will be completed by [CONTACT_641546] (
[CONTACT_685598]
).
 
 
7.
5
.3.1
 
Expedited IND Safety Reports:
 
 
7 Calendar
-
Day Telephone or Fax Report
:  
 
The 
IND 
Sponsor is required to notify the FDA of any fatal or life
-
threatening 
adverse event that is unexpected and assessed by [CONTACT_70724].  Such reports are to be telephoned or faxed 
(301
-
827
-
9796) to the 
FDA within [ADDRESS_929354] learning of the event.  
 
 
15 Calendar
-
Day Written Report
:  
 
The 
IND 
Sponsor is required to notify the FDA of any serious adverse event that 
is unexpected and possibly related to the investigational agent in a written IND
 
Safety Report.  
 
 
Written IND Safety Reports should include an Analysis of Similar Events in 
accordance with regulation 21 CFR § 312.32.  All safety reports previously filed 
with the IND concerning similar events should be analyzed.  The new report 
should
 
contain comments on the significance of the new event in light of the 
previous, similar reports.  
 
 
Written IND safety reports with Analysis of Similar Events are to be submitted 
to the FDA within [ADDRESS_929355] learning of the event. 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
39
 
7.
5
.3.2
 
IND Annual Reports
 
 
In accordance with the regulation 21 CFR § 312.
[ADDRESS_929356] submit a brief report of 
the adverse events and progress of the investigation.  Please refer to C
ode of 
Federal Regulations, 21 CFR § 312.
[ADDRESS_929357] of the elements required for the 
annual report.  All IND annual reports will be submitted to the FDA by [CONTACT_429]
-
Investigator.
 
 
8
.
 
PHARMACEUTICAL
 
INFORMATION
 
(MK
-
3475)
 
 
8
.1
 
Agent Accountability
 
 
The
 
sponsor/investigator shall take responsibility for and shall take all steps to maintain 
appropriate records and ensure appropriate supply, storage, handling, distribution and 
usage of investigational product in accordance with the protocol and any applica
ble 
laws and regulations.
 
8.[ADDRESS_929358] be 
recorded by [CONTACT_131895]. 
 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929359] is intended for IV administration. 
 
 
8.9
 
Patient Care Implications
 
 
 
 
–
 
 
 
 
 
8.10
 
Agent Ordering
 
 
 
 
 
 
 
 
 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
41
 
 
8.11 
 
Returns and Reconciliation
 
 
The investigator is responsible for keepi[INVESTIGATOR_270200], the amount dispensed to, and returned by [CONTACT_270227].
 
 
Upon
 
co
m
pletion
 
or
 
ter
m
ination
 
of
 
the
 
study,
 
all
 
unused
 
and/or
 
partially used 
investigational product will be d
estroyed at the site per institutional policy. It is the 
Investigat
o
r
’s
 
respon
s
ibility
 
to
 
arrange for 
disposal of all empty containers, 
provided that procedures for proper disposal have been established according to 
applicable federal, state, local and ins
titutional guidelines and procedures, and provided 
that appropriate records of disposal are kept.
 
 
9
.
 
CORRELATIVE/SPECIAL STUDIES
 
 
Research samples will be collected at the discretion of the PI [INVESTIGATOR_685578].
 
Sample collection, storage
,
 
and shipment instructions will be 
provided in the 
Procedures Manual
.
 
Research samples may be transferred to external 
collaborators as part of existing or novel research agreements. All transferred samples will be 
deidentified. All transfers will be protected under a Johns Hopkins Material Transfer 
Agreement.
 
 
9.1
 
Tumor Tissue Studies
 
 
Tumor biopsies 
will be collected
 
(if a patient’s tumor is thought to be reasonably safe 
and easy to biopsy) at baseline and 
prior to
 
Cycle 3
 
(4
-
6 cores per timepoint)
. 
Additional optional biopsies may be obtained later in the course of therapy. Archival 
tumor samples will also be collected for every patient
 
(slides and/or blocks)
.
 
Fine 
needle aspi[INVESTIGATOR_133597]. 
Addition
al archival tissue from 
patients no 
longer receiving treatment due to disease
 
progression may also be collected in order to 
evaluate 
resistant lesions. 
Detailed instructions for tissue collection, processing and 
shipment are provided in the procedures manu
al.
 
 
9.1.1 
To explore the association of MSI positive, PD
-
L1 positivity, and tumor 
infiltrating lymphocyte characteristic
s
 
with clinical responses, archived tumor tissue 
and tumor tissue obtained at baseline and during treatment
 
(
prior to cycle 3
) will be 
compared
. 
PD
-
L1 expression 
may predict
 
response to anti
-
PD
-
1 
[
28
, 
51
]
.  However, 
PD
-
L1 is also upregulated in response to IFN
-
γ
 
released by [CONTACT_454] T cells and could 
potentially be a predictor of response to any active immunotherapy
.  Pre and post
-
treatment tumor biopsies will also be analyzed for PD
-
1 expression as well as 
infiltration of immune cells (effector T cells, Tregs, B cells, dendritic cells, etc).  
Characterization of immune checkpoint expression as well as immune infiltr
ates may 
be predictive of response to therapy and may also give insight into next generation 
combinatorial approaches.  
Preliminary data from 
a pancreatic cancer immunotherapy 
study suggests
 
that induction of a T
h
1and T
h
17 phenotype at the tumor itself pre
dicts 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929360] a subset of patients will respond to 
immunotherapy and there may be genetic determinants that define this response.
 
These 
studies will define the genetic la
ndscape of these tumors and may determine an 
‘immune responsive’ phenotype.  Furthermore, since each mutation is a potential neo
-
antigen that may drive an immune response, we will evaluate each mutation for 
antigenic potential in our model
 
[
58
]
.
 
 
9.1.[ADDRESS_929361] for MSI 
status since there is a correlation between MSI status and these mutations.
 
 
Deleterious mutations in the following
 
genes:
 
 

 
MLH 1
 

 
MSH 2
 

 
MSH 6
 

 
PMS2
 

 
BRAF pV600E
 

 
TGFBR2
 
 
9.2 
 
Peripheral Blood Lymphocytes (
PBLs
)
 
 
Post
-
t
reatment
 
expression
 
of 
PD
-
1 and other lymphocyte activation markers
 
will be 
measured and correlated with OS
 
and MSI positivity
.  PBL will be collected 
as 
described in 
Section 10
.  PBL are isolated and stored 
frozen until use
.
 
 
9.3 
 
Serum 
and Plasma 
Marker Studies
 
 
S
era 
and plasma 
will be collected
 
as described in 
Section 10
 
to identify potential 
therapeutic targets, biomarkers, and predictors of response and autoimmune toxicity 
through proteomic approaches
.
 
In
 
addition, we will look at alternative methods to 
identify MSI in circulating tumor DNA. 
Whole blood will be collected in a 10 milliliter 
Serum Separator Tube (SST tube) at the designated time points and processed using 
standard laboratory procedures.  Usi
ng a pi[INVESTIGATOR_8462], aliquots of [ADDRESS_929362] whole blood in 
two 
10 mL plasma preparation tubes with EDTA 
(PPT, BD Vacutainer, Franklin Lakes, NJ) and gently swirl tubes to mix b
lood with 
EDTA.   Within two hours of collection, the sample will be processed using standard 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
43
procedures for plasma separation.  Plasma will be divided into 1 mL aliquots and stored 
at 
-
80
o
C.  Pellets from this separation procedure will be washed in PBS an
d then 
divided into aliquots and also stored at 
-
80
o
C.
 
 
9.4 
 
Normal tissue based studies
 
 
To assess the baseline characteristic of the subjects enrolled and to correlate these 
molecular and clinicopathologic criteria with treatment response and toxicity.  DNA 
will be extracted from whole blood 
(collection and processing described in 9.3) 
and 
us
ed to evaluate for any germline mutations that may correlate with response or 
toxicity.  
A 
SNP array may be performed on each case using the Affymetrix Genome
-
wide Human SNP Array 6.0 (Santa Clara, CA).
 
 
9.[ADDRESS_929363] clinical trial sites
. Detailed instructions for sample collection, 
processing, storage, and shipment are provided in the procedures manual.
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
44
10
.
 
STUDY CALENDAR
 
10.1 
 
Cohorts A
-
C
 
Study Procedures
 
Pre
-
Study
19
 
Cycle
 
(14 days)
 
20
 
20 
Weeks
21
 
Off 
Treatment
 
Off 
Study
2
4
 
Visit Windows (days)
1
 
N/A
 
-
28 to 
-
1
 
+7
 
+/
-
 
14
 
+/
-
 
7
 
+/
-
 
14
 
MK
-
3475
 
 
 
X
 
 
 
 
Pre
-
screening consent
2
 
 
X
 
 
 
 
 
Informed consent
 
 
X
 
 
 
 
 
Inclusion/exclusion criteria
 
 
X
 
 
 
 
 
Demographics
 
 
X
 
 
 
 
 
MSI Testing
 
X
 
 
 
 
 
 
Medical history
 
 
X
 
 
 
 
 
Cancer History
3
 
 
X
 
 
 
 
 
Concurrent meds
 
 
X
 
X
 
X
 
X
22,23
 
X
 
Physical exam
4
 
 
X
 
X
 
X
 
 
X
 
Vital signs
5
 
 
X
 
X
 
X
 
 
X
 
Height
 
X
 
 
 
 
 
 
Weight
 
 
X
 
X
 
X
 
 
X
 
Performance status (PS)
 
 
X
 
X
 
X
 
 
X
 
Hematology 
profile
6, 12
 
 
X
 
X
 
X
 
X
22,23
 
X
 
Chemistry profile
7, 12
 
 
X
 
X
 
X
 
X
22,23
 
X
 
TSH, T3, FT4
8, 12
 
 
 
X
 
X
 
X
22,23
 
X
 
Urinalysis
9, 12
 
 
X
 
 
 
 
 
B
-
HCG
10, 12
 
 
X
 
 
 
 
 
Serum Tumor Markers
11, 12
 
 
X
 
X
 
X
 
X
22,23
 
X
 
Adverse event evaluation
 
 
 
X
 
X
 
X
22,23
 
X
 
Radiologic evaluation
13
 
 
X
 
X
 
X
 
X
23
 
 
Tumor measurements
13
 
 
X
 
X
 
X
 
 
 
Whole blood for PBL
14
 
 
 
X
 
X
 
X
23
 
 
Serum (approximately 10cc)
 
14
 
 
 
X
 
X
 
X
23
 
 
Whole Blood Sample for Plasma 
(approximately
 
 
20cc)
 
14
 
 
 
X
 
X
 
X
23
 
 
Stool/Saliva Sample
15
 
 
X
 
X
 
 
 
 
Archival Tissue
16
 
 
X
 
X
 
 
X
 
X
 
Tumor 
Biopsies
17
 
 
X
 
X
 
 
 
 
Buccal Swab/purple top tube
18
 
 
X
 
X
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
45
1:
 
Longer delays to be approved by [CONTACT_70737] 
S
ponsor.
 
2: 
Pre
-
screening informed consent for MSI testing (Cohort C only). 
 
3:
 
Cancer history includes: primary site of cancer, 
gross location of primary tumor, 
secondary sites of cancer, 
histology, histologic grade, date of initial diagnosis, date of metastatic diagnosis
, prior cancer therapy regimens.
 
4
:
 
Complete physical exam will be completed at baseline; focused physical exami
nations will be conducted thereafter.
  
Exams, concomitant medication, AE assessments can be made up to 3 days prior to infusion.
 
5
: Temperature, blood pressure,
 
pulse
, and pulse oximetry
 
should be taken 
at baseline
 
and
 
prior to 
each 
MK
-
3475
 
infusion
.
  
 
6
: 
CBC with differential including absolute eosinophil count, absolute neutrophils, absolute lymphocytes, and platelets.
 
7
: 
Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, 
total protein, 
SGOT [AST], SGPT [ALT], sodium.
 
8
: 
TSH
,
 
Total T3
,
 
and Free T4
 
will be collected at baseline (Day 
-
28 to Day 1), 12 weeks (+/
-
 
2 week), every 8 weeks 
(+/
-
 
2 week) through week 52, and then every 12 weeks (+/
-
 
2 week) thereafter
 
including the off study evalu
ation
. 
Weeks are in reference to calendar week and should not be adjusted due to dosing delays
.
 
 
9
: B
ilirubin, blood, glucose, ketones, leukocytes, nitrite, pH, 
color, 
protein, 
RBC and WBC count, 
and specific gravity.
 
10
: 
 
Serum 
or urine 
pregnancy test 
(women of childbearing potential).
 
11
: 
D
isease specific tumor markers where appropriate.
 
 
12
: 
Labs may be collected within a window of up to 3 days prior to dosing.
 
1
3
: 
Radiologic evaluations and tumor measurements will be performed
 
at baseline
 
(within [ADDRESS_929364] 
dose of MK
-
3475)
, 12 weeks
 
(+/
-
 
2 
week)
,
 
every 
8 
weeks
 
(+/
-
 
2 
week
)
 
through week 52
, and then every 12 weeks 
(+/
-
 
2 week) 
thereafter
.
 
Weeks are in reference to calendar week and should not be adjusted due to dosing delays.
 
14
:
 
See 
Correlative Studies table below for further details.
 
15
: 
Samples to be obtained at 
baseline and 
with each scan [12 weeks (+/
-
 
2 week), every 8 weeks (+/
-
 
2 week) through 
week 52, and then every 12 weeks (+/
-
 
2 week) thereafter] 
at 
select clinical trial 
sites. Detailed instructions regarding 
collection and processing are located in the Procedures Manual.
 
 
16
: 
Attempts to obtain a
rchival tumor samples will be 
made for every patient until the sample is obtained or 
documentation that the sample cannot be obt
ained
. 
Th
e tissue sample should have proper size to enable IHC analysis 
of PD
-
L1. 
Fine needle aspi[INVESTIGATOR_270201]. Detailed instructions for tissue collection, processing and 
shipment are provided in the Procedures Manual.
 
 
17
:
 
 
Tumor biopsies
 
to be taken (if a patient’s tumor is thought to be reasonably safe and easy to biopsy) at baseline and 
prior to Cycle 3
 
(4
-
6 cores per timepoint)
. 
The biopsy performed prior to Cycle [ADDRESS_929365] proper size to enable IHC analysis of PD
-
L1. Fine needle aspi[INVESTIGATOR_133597]. Detailed 
instructions for tissue collection, processing and shipment are prov
ided in the Procedures Manual.
 
18
: Buccal swabs
 
and/or purple top tube
 
will be obtained only for those patients who do n
ot
 
have en
ough
 
norma
l
 
tissue 
for M
SI
 
testing.
  
This collection can occur any time after consent.
 
19
: 
Patients who stop MK
-
3475 with SD 
or better may be eligible for up to one year of additional MK
-
3475 therapy if 
they progress after stoppi[INVESTIGATOR_270196]
-
3745
,
 
they meet the criteria listed in 
Section 5.
7
.2, 
and
 
undergo 
the following 
evaluations: 
interval medical and cancer history, 
physical exam, vitals, weight, PS, hematology and chemistry 
profile, autoimmune and endocrine panel, urinalysis, 
serum or urine pregnancy test
, serum tumor markers, 
radiographic evaluations, and tumor measurements
.
 
The following samples will be collected a
t baseline and while 
on study: peripheral blood, serum, whole blood for plasma, and biopsy. Subjects who restart treatment after relapse 
should resume at the same dose and cycle interval which they were receiving prior to discontinuation.
 
20
: For cycle 1, 
study procedures do not need to be repeated if they were conducted within 3 days of the pre
-
study 
evaluations.
 
21
: 
Week 20 evaluations
 
(calculated from the date of the first dose)
, which include additional blood, CT
/MRI
 
scans 
and tumor measurements, may co
incide with a cycle visit.
   
All week [ADDRESS_929366] be completed at the Week 
20 time point
.
 
22: Patients will undergo the Off Treatment Evaluation 
30 days (+/
-
 
7 days) after the last infusion of MK
-
3475 
if they 
completed 24 months of MK
-
3475 
treatment
 
or the patient has discontinued MK
-
3475 after an investigator 
determined confirmed CR
 
(
Section 5.
7
.1
). The
 
assessment of AEs and medications can be made either as part of a 
clinical visit or over the phone.
 
Patients will also continue to be monit
ored for 
the
 
resolution of drug
-
related AEs to 
≤ Grade 1. SAEs that occur within [ADDRESS_929367] infusion of MK
-
3475 or before initiation of a new 
antineoplastic treatment shoul
d also be followed and recorded
.
 
23: 
While off treatment
 
(
Section 5.7.1
)
, p
atients should continue to be monitored by [CONTACT_70719]
, clinical labs,
 
and tumor marker(s) 
approximately 
every 12 weeks 
for 
3
 
year
s
 
(
timing calculated from the first dose of MK
-
3475)
. 
After 3 years, these assessments will be done approximately every
 
6 months and then annually after 5 years while 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929368]
.
 
 
2
4
:
 
 
[ADDRESS_929369].
 
Patients who 
come off study should 
continue to be followed
 
as described in 
Section 5.9.
 
 
 
Correlative Studies 
While On study
 
 
Baseline
 
2 
Weeks
 
4 
Weeks
 
12 
Weeks
 
20 
Weeks
 
Q 8 Weeks
 
(Weeks 28
-
 
52)
 
Q 12 Weeks
 
(week 64 
and beyond)
 
Whole blood for PBL
 
1
 
X
2
 
X
2
 
X
2
 
X
3
 
X
3
 
X
3
 
X
3
 
Serum (approximately 
10cc)
 
1
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Whole Blood 
Sample 
for Plasma 
(approximately
 
 
20cc)
 
1
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
 
1: Blood and serum samples will be collected at baseline
 
(Day 
-
28 to Day 1)
, 2 weeks
 
(+/
-
 
1 
 
week)
, 4 weeks
 
(+/
-
 
1 
 
week)
, 12 weeks (+/
-
 
2 
week), every 8 weeks (+/
-
 
2 
week) 
through
 
week
 
52
, and then every 12 weeks 
(+/
-
 
2 week) 
thereafter.
 
Weeks are in reference to calendar week and should not be 
adjusted
 
due to dosing delays.
 
2: Up to 64 cc
 
3: Up to 100 cc
 
 
Correlative Studies 
While Off Treatment (per Section 5.7.1)
 
 
C
linical or 
radiographic response of interest
 
 
Whole blood for PBL
 
(up to 100cc)
 
X
 
Serum (approximately 10cc)
 
 
X
 
Whole Blood Sample for Plasma 
(approximately
 
 
20cc)
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
47
10.2 
 
Cohort D
 
Study Procedures
 
Pre
-
Study
19
 
Cycle
 
(21 days)
 
20
 
21 
Weeks
21
 
Off 
Treatment
 
Off 
Study
2
4
 
Visit Windows (days)
1
 
N/A
 
-
28 to 
-
1
 
-
3/+7
 
+/
-
 
14
 
+/
-
 
7
 
+/
-
 
14
 
MK
-
3475
 
 
 
X
 
 
 
 
Pre
-
screening consent
2
 
 
X
 
 
 
 
 
Informed consent
 
 
X
 
 
 
 
 
Inclusion/exclusion criteria
 
 
X
 
 
 
 
 
Demographics
 
 
X
 
 
 
 
 
MSI 
and 
mutator phenotype testing
 
X
 
 
 
 
 
 
Medical history
 
 
X
 
 
 
 
 
Cancer History
3
 
 
X
 
 
 
 
 
Concurrent meds
 
 
X
 
X
 
X
 
X
22,23
 
X
 
Physical exam
4
 
 
X
 
X
 
X
 
 
X
 
Vital signs
5
 
 
X
 
X
 
X
 
 
X
 
Height
 
X
 
 
 
 
 
 
Weight
 
 
X
 
X
 
X
 
 
X
 
Performance status (PS)
 
 
X
 
X
 
X
 
 
X
 
Hematology profile
6, 12
 
 
X
 
X
 
X
 
X
22,23
 
X
 
Chemistry 
profile
7, 12
 
 
X
 
X
 
X
 
X
22,23
 
X
 
TSH, T3, FT4
8, 12
 
 
 
X
 
X
 
X
22,23
 
X
 
Urinalysis
9, 12
 
 
X
 
 
 
 
 
B
-
HCG
10, 12
 
 
X
 
 
 
 
 
Serum Tumor Markers
11, 12
 
 
X
 
X
 
X
 
X
22,23
 
X
 
Adverse event evaluation
 
 
 
X
 
X
 
X
22,23
 
X
 
Radiologic evaluation
13
 
 
X
 
X
 
X
 
X
23
 
 
Tumor measurements
13
 
 
X
 
X
 
X
 
 
 
Whole blood for PBL
14
, 25
 
 
 
X
 
X
 
X
23
 
 
Serum (approximately 10cc)
 
14
, 25
 
 
 
X
 
X
 
X
23
 
 
Whole Blood Sample for Plasma 
(approximately
 
 
20cc)
 
14
, 25
 
 
 
X
 
X
 
X
23
 
 
Stool/Saliva Sample
15
, 25
 
 
X
 
X
 
 
 
 
Archival Tissue
16
, 25
 
 
X
 
X
 
 
X
 
X
 
Tumor Biopsies
17
, 25
 
 
X
 
X
 
 
 
 
Buccal Swab/purple top tube
18
,25
 
 
X
 
X
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
48
In order to minimize the need for research
-
only in
-
person visits, telemedicine visits may be substituted for in person 
clinical trial visits or portions of clinical trial visits where determined to be appropriate
 
and where determined by [CONTACT_685591]. Prior to initiating telemedicine for study visits the study team will 
explain to the participant, what a telemedicine visit entails and confirm that the study participant is 
in agreement and 
able to proceed with this method. Telemedicine acknowledgement will be obtained in accordance with the Guidance 
for Use of Telemedicine in Research. In the event telemedicine is not deemed feasible, the study visit will proceed as 
an in
-
pe
rson visit. Telemedicine visits will be conducted using HIPAA compliant method approved by [CONTACT_685592].
 
 
1:
 
Longer delays to be approved by [CONTACT_270229].
 
2: Pre
-
screening informed consent for MSI testing (Cohort C only). 
 
3:
 
Cancer history includes: primary site of cancer, gross location of primary tumor, secondary sites of cancer, 
histology, histologic grade, date of initial diagnosis, date of metastatic 
diagnosis, prior cancer therapy regimens.
 
4:
 
Complete physical exam will be completed at baseline; focused physical examinations will be conducted thereafter.  
Exams, concomitant medication, AE assessments can be made up to 3 days prior to infusion.
 
5: Tem
perature, blood pressure, pulse
, and pulse oximetry
 
should be taken at baseline
 
and
 
prior to 
each 
MK
-
3475 
infusion.
 
6: 
CBC with differential including absolute eosinophil count, absolute neutrophils, absolute lymphocytes, and platelets.
 
7: Albumin, alkalin
e phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, 
total protein, SGOT [AST], SGPT [ALT], sodium.
 
8: 
TSH
,
 
Total T3
,
 
and Free T4 will be collected at baseline (Day 
-
28 to Day 1), 12 weeks (+/
-
 
2 week), every
 
9 weeks 
(+/
-
 
2 week) through week 57, and then every 12 weeks (+/
-
 
2 week) thereafter
 
including the off study evaluation
. 
Weeks are in reference to calendar week and should not be adjusted due to dosing delays. 
 
9: B
ilirubin, blood, glucose, ketones, leuk
ocytes, nitrite, pH, color, protein, RBC and WBC count, and specific gravity.
 
10: 
 
Serum or urine pregnancy test (women of childbearing potential).
 
11: Disease specific tumor markers where appropriate. 
 
12: Labs may be collected within a window of up to 3 
days prior to dosing.
 
13: Radiologic evaluations and tumor measurements will be performed at baseline (within [ADDRESS_929370] 
dose of MK
-
3475), 12 weeks (+/
-
 
2 week), every 9 weeks (+/
-
 
2 week) through week 57, and then every 12 weeks 
(+/
-
 
2 wee
k) thereafter. Weeks are in reference to calendar week and should not be adjusted due to dosing delays.
 
14: See Correlative Studies table below for further details.
 
15: Samples to be obtained at baseline and with each scan [12 weeks (+/
-
 
2 week), every 9 w
eeks (+/
-
 
2 week) through 
week 57, and then every 12 weeks (+/
-
 
2 week) thereafter] at select clinical trial sites. Detailed instructions regarding 
collection and processing are located in the Procedures Manual. 
 
16: Attempts to obtain archival tumor sampl
es will be made for every patient until the sample is obtained or 
documentation that the sample cannot be obtained. The tissue sample should have proper size to enable IHC analysis 
of PD
-
L1.  Fine needle aspi[INVESTIGATOR_270201]. Detailed instructi
ons for tissue collection, processing and 
shipment are provided in the Procedures Manual. 
 
17:
 
 
Tumor biopsies to be taken (if a patient’s tumor is thought to be reasonably safe and easy to biopsy) at baseline and 
prior to Cycle 3
 
(4
-
6 cores per timepoint)
. The biopsy performed prior to Cycle [ADDRESS_929371] proper size to enable IHC analysis of PD
-
L1. Fine needle aspi
[INVESTIGATOR_133597]. Detailed 
instructions for tissue collection, processing and shipment are provided in the Procedures Manual.
 
18: Buccal swabs and/or purple top tube will be obtained only for those patients who do not have enough normal tissue
 
for MSI testing.  This collection can occur any time after consent.
 
19: 
Patients who stop MK
-
3475 with SD or better may be eligible for up to one year of additional MK
-
3475 therapy if 
they progress after stoppi[INVESTIGATOR_270196]
-
3745,
 
they meet the criteria listed in 
Section 5.7.2, 
and
 
undergo the following 
evaluations: interval medical and cancer history, physical exam, vitals, weight, PS, hematology and chemistry 
profile, autoimmune and endocrine panel, urinalysis, serum or urine pregnancy test, serum tumor markers, 
radiographic evaluations, and tumor measurements. The following samples will be collected at baseline and while 
on study: peripheral blood, serum, whole blood for plasma, and biopsy. Subjects who restart treatment after relapse 
should resume at the same do
se and cycle interval which they were receiving prior to discontinuation.
 
20: For cycle 1, study procedures do not need to be repeated if they were conducted within 3 days of the pre
-
study 
evaluations.
 
21: Week 21 evaluations (calculated from the date of t
he first dose), which include additional blood, CT/MRI scans 
and tumor measurements, may coincide with a cycle visit.   All week [ADDRESS_929372] be completed at the Week 
21 time point.
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
49
22: 
Patients will undergo the Off Treatment Evaluation 30 days (+/
-
 
7 days) after the last infusion of MK
-
3475 if they 
completed 24 months of MK
-
3475 treatment
 
or the patient has discontinued MK
-
3475 after an investigator 
determined confirmed CR 
(
Section 5.7.1
). The
 
assessment of AEs and medications can be made either as 
part of a 
clinical visit or over the phone. 
Patients will also continue to be monitored for the resolution of drug
-
related AEs to 
≤ Grade 1. SAEs that occur within [ADDRESS_929373] infusion of MK
-
3475 or before initiation of a new 
antineoplastic treatme
nt should also be followed and recorded
.
 
23: 
While off treatment (
Section 5.7.1
), p
atients should continue to be monitored by [CONTACT_70719]
, clinical labs,
 
and tumor marker(s) 
approximately 
every 12 weeks 
(
timing calculated 
from the first dose of MK
-
3
475). After [ADDRESS_929374]
.
 
2
4
:
 
 
[ADDRESS_929375]. Patients 
who 
come off study should continue to be followed as described in 
Section 5.9.
 
25: 
Research samples will be collected at the discretion of the PI [INVESTIGATOR_685579].
 
 
Correlative Studies 
While On Study
 
 
 
Bas
eline
 
3 
Weeks
 
6 
Weeks
 
12 
Weeks
 
21 
Weeks
 
Q 9 Weeks
 
(Weeks 
30
-
 
57)
 
Q 
24
 
Weeks 
(week 
81
 
and beyond)
 
Whole blood for PBL
 
1
 
X
2
 
X
2
 
X
2
 
X
3
 
X
3
 
X
3
 
X
3
 
Serum (approximately 
10cc)
 
1
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Whole Blood Sample 
for Plasma 
(approximately
 
 
20cc)
 
1
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
 
1: Blood and serum samples will be collected at baseline (Day 
-
28 to Day 1), 3 weeks (+/
-
 
1  week), 6 weeks 
(+/
-
 
1  week), 12 weeks (+/
-
 
2 week), every 9 weeks (+/
-
 
2 week) through week 57, and then every 
24
 
weeks 
(+/
-
 
2 week) thereafter. Weeks are in refe
rence to calendar week and should not be adjusted due to dosing delays.
 
2: Up to 64 cc
 
3: Up to 100 cc 
 
 
 
Correlative Studies 
While Off Treatment (per Section 5.7.1)
 
 
C
linical or radiographic response of 
interest
 
 
Whole blood for PBL
 
(up to 
100cc)
 
X
 
Serum (approximately 10cc)
 
 
X
 
Whole Blood Sample for Plasma 
(approximately
 
 
20cc)
 
 
X
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929376] 
–
 
Solid Tumors
 
 
For the purposes of this study, patients should be evaluated for response 
at the 12 week 
timepoint
,
 
every 
8 weeks
 
through week 52
, and then every 12 weeks thereafter 
including the off study evaluation
.  Response and progression will be evaluated in this 
study using the new international criteria proposed by [CONTACT_685593] (RECIST) guideline (version 1.1) [
Appendix 
E
]
 
and the 
immune related Response criteria (irRC)  
[
Appendix 
F
]
.
  
Tumor assessments in the 
second expansion 
cohort
 
will be evaluated by [CONTACT_393] 1.[ADDRESS_929377] diameter (unidime
nsional measurement) of the tumor lesions and the shortest 
diameter in the case of malignant lymph nodes are used in the RECIST criteria.
 
RECIST and irRC response assessments will be performed locally for the trial and 
may 
be requested for central review.
 
 
11.1.[ADDRESS_929378]
ing to the definitions stated below.  (Note:  
Patients who exhibit objective disease progression prior to the end of cycle 1 will 
also be considered evaluable.)
 
 
Evaluable Non
-
Target Disease Response
.  Patients who have lesions present at 
baseline that are
 
evaluable but do not meet the definitions of measurable disease, 
have received at least one cycle of therapy, and have had their disease re
-
evaluated 
will be considered evaluable for non
-
target disease.  The response assessment is 
based on the presence, a
bsence, or unequivocal progression of the lesions. 
 
 
11.1.
2
 
Methods for Evaluation of Measurable Disease
 
 
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closely 
as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.
 
 
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during fol
low
-
up. 
Imaging
-
based evaluation is preferred to evaluation by [CONTACT_99237](s) being followed cannot be imaged but are assessable by [CONTACT_461].
 
 
Conventional CT and MRI
:
 
This guideline has defined measurability of lesions on 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929379] slice thickness greater than 5 mm, the minimum size for a measurable 
lesion should be twice the slice thickness.  MRI is also acceptable in certain 
situations (e.g. f
or body scans).  
 
 
Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and 
temporal resolution; however, there are many image acquisition variables involved 
in MRI, which greatly impact image quality, lesion conspi[INVESTIGATOR_3934], and measuremen
t.  
Furthermore, the availability of MRI is variable globally.  As with CT, if an MRI 
is performed, the technical specifications of the scanning sequences used should be 
optimized for the evaluation of the type and site of disease.  Furthermore, as with 
CT
, the modality used at follow
-
up should be the same as was used at baseline and 
the lesions should be measured/assessed on the same pulse sequence.  It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence 
parameters for all
 
scanners, body parts, and diseases.  Ideally, the same type of 
scanner should be used and the image acquisition protocol should be followed as 
closely as possible to prior scans.  Body
 
scans should be performed with breath
-
hold scanning techniques, if pos
sible.
 
 
PET
-
CT:  A PET
-
CT can be used to obtain the images as long as the CT is of 
diagnostic quality.  
 
 
11.1.
[ADDRESS_929380] 1.1 
and irRC
 
 
Duration of overall response
:  The duration of overall response is measured from 
the time 
measurement criteria are met for CR or PR (whichever is first recorded) 
until the first date that recurrent or progressive disease is objectively documented 
(taking as reference for progressive disease the smallest measurements recorded 
since the treatment
 
started).
 
 
The duration of overall CR is measured from the time measurement criteria are first 
met for CR until the first date that progressive disease is objectively documented.
 
 
 
Duration of stable disease
:  Stable disease is measured from the start of the 
treatment until the criteria for progression are met, taking as reference the smallest 
measurements recorded since the treatment started, including the baseline 
measurements. 
In order to be considered dur
able, Stable Disease must be 
maintained for at least 6 weeks (this will be attained by [CONTACT_941] 
9 
week time point)
.
 
 
11.1.
4
 
Progression
-
Free Survival
 
(PFS)
 
as per RECIST 1.[ADDRESS_929381].
 
 
 
11.1.
5
 
Overall Survival
 
(OS)
 
 
 
 
OS is defined as the duration of time from start of treatment to time of deat
h
.
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
52
 
12
.
 
 
DATA REPORTING / 
REGULATORY REQUIREMENTS
 
 
Adverse event guidelines and instructions for AE reporting can be found in 
Section 7.0
 
(Adverse 
Events: List and Reporting Requirements)
.
 
 
12.1
 
Data Management
 
 
All information will be collected on study
-
specific case report forms (CRFs) by [CONTACT_38992]. 
These data will be reviewed for completeness and accuracy by [CONTACT_9532]
 
[INVESTIGATOR_12758]
. 
 
 
Protocol Chair
 
The Protocol Chair is responsible for performing the following tasks:
 

 
Coordinating, developi[INVESTIGATOR_007], submitting, and obtaining approval for th
e protocol as well 
as its subsequent amendments.
 

 
Assuring that all participating institutions are using the correct version of the 
protocol.
 

 
Taking responsibility for the overall conduct of the study at all participating 
institutions and for monitoring the
 
progress of the study.
 

 
Reviewing and ensuring reporting of Serious Adverse Events (SAE)
 

 
Reviewing data from all sites.
 
 
Coordinating Center
 
The Coordinating Center is responsible for performing the following tasks:
 

 
Ensuring that IRB approval has been obta
ined at each participating site prior to the 
first patient registration at that site, and maintaining copi[INVESTIGATOR_54923].
 

 
Managing central patient registration.
 

 
Collecting and compi[INVESTIGATOR_54924].
 

 
Establishing procedures for d
ocumentation, reporting, and submitting of AE’s and 
SAE’s to the Protocol Chair, and all applicable parties.
 

 
Facilitating audits by [CONTACT_54965], or by [CONTACT_685594].
 
 
Participating Sites
 
Participating sites are responsible for performing the following tasks:
 

 
Following the protocol as written, and the guidelines of Good Clinical Practice 
(GCP).
 

 
Submitting data to the Coordinating Center.
 

 
Registering all patients 
with the Coordinating Center by [CONTACT_54967], and signed informed consent promptly.
 

 
Providing sufficient experienced clinical and administrative staff and adequate 
facilities and equipment to conduct a collaborative trial according 
to the protocol.
 

 
Maintaining regulatory binders on site and providing copi[INVESTIGATOR_484418].
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
53

 
Collecting and submitting data according to the schedule specified by [CONTACT_760].
 
 
[ADDRESS_929382] weekly and will include the protocol principal 
investigator, study coordinator(s), data manager(s), sub
-
investigators (as appropriate), 
collaborators (as appropriate), and biostatisticians (as appropriate) involved with the 
conduct of the 
protocol. During these meetings matters related to the following will be 
discussed: safety of protocol participants, validity and integrity of the data, enrollment 
rate relative to expectation, characteristics of participants, retention of participants, 
ad
herence to protocol (potential or real protocol violations), data completeness, and 
progress of data for objectives.
 
 
Monthly teleconferences will be scheduled
 
to include the Investigator and [COMPANY_006] 
representatives.
 
D
uring 
these meetings, 
the 
Investigator 
s
hall provide [COMPANY_006] with study 
progress updates
.  The Investigator will provide a summary of key points from the 
weekly meetings with a focus on safety of the protocol participants, enrollment status, 
and progress of data for objectives.  In addition, [COMPANY_006]
 
will provide safety and 
applicable program updates to the Sponsor.
 
 
12.3 
 
Monitoring
 
 
The SKCCC Compliance Monitoring Program will provide external monitoring for 
JHU
-
affiliated sites in accordance with SKCCC DSMP (Version 6.0, 02/21/2019).  The 
SMC 
Subcommittee will determine the level of patient safety risk and level/frequency 
of monitoring
. 
Eligibility for all sites will be monitored by [CONTACT_36476]. The PI 
[INVESTIGATOR_685580], including review and 
confirmation of all safety/treatment
-
related outcomes, response assessments, safety 
reports and/or any related source documentation.
 
Additional data and safety monitoring 
oversight will also be performed by [CONTACT_469] (SMC 
-
 
as d
efined in the DSMP)
. 
The protocol will be monitored internally by [CONTACT_9532] [INVESTIGATOR_12758]. External monitoring will occur according to the following 
guidelines:
 
 
Johns Hopkins SKCCC
: The protocol will be monitored externally by [CONTACT_685595]. Trial monitoring and reporting will be 
done through the Safety Monitoring Committee (SMC) at SKCCC. 
 
 
Participating site(s)
: The p
rotocol will be monitored by
 
[CONTACT_685596]
. 
A report of the reviews will be submitted to 
the 
Johns Hopkins principal investigator 
[INVESTIGATOR_270203].
 
 
Authorized representatives of the Coordinating Center may visit the satellite sites to 
perform audits or inspections, incl
uding source data verification. The purpose of these 
audits or inspections is to systematically and independently examine all trial
-
related 
activities and documents to determine whether these activities were conducted and data 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
54
were recorded, analyzed, and 
accurately reported according to the protocol, Good 
Clinical Practice (GCP), and any applicable regulatory requirements.
 
 
[CONTACT_685598]
 
is
 
holding the IND for this study.  
Sh
e
 
will comply with all regulated reporting 
requirements to the FDA.
 
 
1
3
.
 
STATISTICAL 
CONSIDERATIONS
 
 
13.1
 
Study Design/Endpoints
 
 
This is a multicenter, open
-
label, 
two
-
stage, phase 
2
 
study to evaluate the clinical 
activity of MK
-
3475 in MSI positive and MSI negative solid tumors.  We will enroll 
three cohorts of patients:  patients with MSI positive 
colorectal adenocarcinomas
 
(
Cohort A
); patients with MSI negative col
orectal adenocarc
inomas
 
(
Cohort B
); and 
patients with MSI positive solid tumor
 
malignancies 
but not colo
rectal adenocarcinoma
 
(Cohort C); all cohorts will receive MK
-
3475.
 
Each cohort will be assessed separately.  
This design aims to 
evaluate 
MSI as a biomarker and evaluat
e treatment benefit 
simultaneously.
 
 
The primary endpoint
s
 
for Cohort
s
 
A
 
and B
 
are
 
immune
-
related progression
-
free 
survival (irPFS) rate 
at 
20
 
weeks and objective response rate (irORR) 
assessed using 
immune related response criteria (irRC)
; irPFS is
 
define
d as the proportion of subjects 
alive and free of disease progression at 
20
 
weeks per irRC;
 
and irORR is the proportion 
of subjects whose best overall response is a CR or PR.
 
 
The primary endpoint for Cohort C is immune
-
related progression
-
free survival (i
rPFS) 
rate assessed using immune related response criteria (irRC) at 
20 
weeks, defined as the 
proportion of subjects alive and free of disease progression at 
20
 
weeks per irRC.  
Each 
cohort will be assessed separately.
 
 
 
The primary endpoint for Cohort D will be 
objective
 
response rate
 
(ORR)
, which is 
defined as the proportion of subjects who have response of CR or PR.  
 
 
The secondary efficacy endpoints include overall survival, progression
-
free survival 
according to
 
RECI
ST 1.1 (PFS), best overall response (BOR), duration of objective 
response (DOOR), time to objective response (TDOR), and disease control rate (DCR) 
per RECIST 1.1, and irPFS, irBOR,  irDOOR, irTDOR, irDCR per irRC. 
 
 
We will also evaluate safety and toxici
ty of MK
-
3
475.
 
We will evaluate exploratory 
endpoints of p
harmacogenomics
 
and predictive biomarkers for responses. 
 
 
 
 
 
13.2
 
Sample Size/Accrual Rate
 
 
For 
C
ohort
 
A
 
and B
, 
a
 
total of [ADDRESS_929383] for further evaluation if 
the irPFS rate at 
20
 
weeks is 5% (p
10
) or less 
or irORR is 5% (
p
20
)
 
or less, 
and 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
55
considered active if the irPFS rate at 
20
 
weeks is 25% or greater (p
1
1
)
 
and irORR is 
21
%
 
or greater (
p
21
)
.
 
We will apply a step
-
down gatekeepi[INVESTIGATOR_685581] a 
study
-
wise type I error rate at 0.[ADDRESS_929384] with irPFS at 
20
 
weeks. 
If the null hypothesis of 
20
-
week irPFS being 5% is 
rejected (i.e. the result reaches statistical significance), we will proceed to test for 
irORR. If irPFS is not significant at the 0.05 level
 
(one
-
sided
 
test
)
, 
the statistical testing 
for irORR will not occur. 
Twenty
-
five patients 
in
 
C
ohort
 
A
 
and B
 
would provide 90
% 
power to detect an improved irPFS rate at 
20
 
weeks from 5% to 25%, a 20% increase, 
at significance level 
of 0.[ADDRESS_929385]
.
  
For an i
mproved irORR from 
5% to 21%, a total of 25
 
patients would provide 80% power to detect an
 
of 
16
% increase 
using a one
-
sided exact binomial test at a 0.[ADDRESS_929386] for the endpoint of irORR for that 
cohort. If 4 or more responders (CR or PR) are observed, we conclude 
the regimen is 
promising 
with that cohort 
and 
warrant
s
 
further study.
 
 
There is a 
1.3
% probability of stoppi[INVESTIGATOR_270205] p
1
1
 
(i.e. incorrectly stoppi[INVESTIGATOR_270206]) and a 
46
% 
probability o
f stoppi[INVESTIGATOR_270207] p
10
 
(i.e. correctly stoppi[INVESTIGATOR_270208]).
 
 
For Cohort D, 
t
he regimen would be considered of insufficient activity for further study 
if 
the response rate is 5% or less, and the minimum required level of efficacy that would 
warrant further study with the proposed regimen is a 21% response rate. A two
-
stage 
Green
-
Dahlberg design is planned. 
A
 
total of [ADDRESS_929387]
 
stage. 
If zero response is observed, that cohort will be terminated and we will conclude 
the regimen is ineffective. If 
>
1 subjects respond, then additional 15 subjects will be 
studied for that cohort.  If 
<
 
4 subjects respond in stage one and two combine
d, we 
consider this regimen ineffective. If 
>
5 responses are observed, we conclude the 
regimen is promising and warrant further study. Each cohort could also be terminated 
as soon as 5 responses are observed before the total cohort is enrolled o
r
 
evaluated
 
in 
that cohort. The maximum sample size will be 35 for each cohort. This design provides 
90% power to detect an absolute difference of 16% of response with a type I error of 
0.05. There is a 36% chance to stop the trial early for futility under 5% respons
e rate.  
Tumor assessments for Cohort D will be evaluated by [CONTACT_393] 1.[ADDRESS_929388] for further evaluation if the irP
FS rate at 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
56
20
 
weeks is 5% (p
0
) or less and considered active if the irPFS rate at 
20
 
weeks is 25% 
or greater (p
1
). 
 
 
A two
-
stage Green
-
Dahlberg design is used for Cohort C. 
An interim analysis will be 
conducted in order to assess futility after irPFS at 
[ADDRESS_929389] one patient is free of disease progression at 
20
 
weeks per irRC, 
an additional 
7
 
evaluable 
subjects will be enrolled into 
C
ohort
 
C
. If 3 or fewer patients 
are progression free at 
20
 
weeks in the total of 
21
 
evaluable 
patients enrolled in 
C
ohort
 
C
, then the regimen will be considered inactive in that cohort. If 4 or more patients are 
progression 
free at 
20
 
weeks, we conclude the regimen is promising and warrant
s
 
further study
 
this patient population
.
 
 
This design provides 
81
% power to detect an improved irPFS rate at 
20
 
weeks from 
5% to 
25
%
 
in Cohort C respectively
, a 
20
% increase, with a type I error of 0.05. There 
is a 
1.
8
% probability of stoppi[INVESTIGATOR_270205] p
1
 
(i.e. 
incorrectly stoppi[INVESTIGATOR_270206]) and a 
4
9
% probability 
of stoppi[INVESTIGATOR_685582] t
he null hypothesis p
0
 
(i.e. correctly stoppi[INVESTIGATOR_270209]).
 
 
As of 28Jan2015, four irPFS at [ADDRESS_929390] 1.1 criteria only.
 
 
 
13.3
 
Stratification 
Factors
 
 
We will enroll 
four
 
cohorts of patients based on disease and MSI
 
or mutator phenotype
 
status: patients with MSI positive colo
rectal adenocarcinomas
 
(
Cohort A
); patients with 
MSI negative colo
rectal adenocarcinomas
 
(
Cohort B
); and patients with MSI
 
positive 
solid tumor
 
malignancies
 
but not colo
rectal adenocarcinoma
 
(Cohort C);
 
and patients 
with MSI negative solid tumor malignancies that have a 
documented mutation burden 
level measured at 
>
 
2
0 mutations per megabase pairs (MB) 
(Cohort D)
.
 
 
13.4
 
Analy
sis of Primary Endpoints
 
 
For Cohort A
 
and B
, immune
-
related progression
-
free survival (irPFS) rate 
at 
20
 
weeks 
and objective response rate (irORR) 
assessed using immune related response criteria 
(irRC) 
are co
-
primary 
endpoints. 
 
irPFS rate at 
20
 
weeks
 
will be estimated 
as the 
proportion of patients alive and free of disease progression at 
20
 
weeks per irRC, along 
with its 95% confidence interval (CI
); 
irORR will be estimated as the proportion of 
subjects whose best overall response is either a CR or PR
 
with corresponding 95% CI. 
The patients who drop out of the study due to toxicity and do not have a follow
-
up scan 
will be considered non
-
responders. 
The formal statistical testing for irORR will take 
place only if 
20
-
week irPFS is statistically significan
t. 
For Cohort C, irPFS will be the 
primary endpoint. 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929391] 1.1 criteria only
, and ORR will be the 
primary endpoint for the expanded Cohort A and 
Cohort C. 
 
 
On 23May2017, FDA approved 
MK
-
3475
 
(pembrolizumab) for the treatment of adult 
and pediatric patients with unresectable or metastatic solid tumors th
a
t 
are MSI
-
H
 
or 
mismatch repair deficient. The recommended dose is 200mg for adults every 3 week
s. 
After the approval patients may
 
receive this new lower dose. 
We will continue follow
-
up of the patients for dis
ease progression and death after FDA approval. The analysis 
for PFS will be performed in two ways
; t
he primary analysis will censor all patients at 
the date of 
the last 
tumor assessment prior to starting the treatment at the FDA
-
approved lower dose, if they do not have disease progression at or prior to that date. A 
secondary analysis
 
will define 
PFS as 
the time from 
the first day of study treatment
 
to the date of the first documented tumor progression or death due to any 
cause, whichever occurs first
, during the entire follow
-
up period
. Subjects 
who did not progress or die will be censored on the date of
 
their last 
evaluable tumor assessment. 
 
  
   
 
 
The evaluable population includes all subjects who receive at least one
 
dose of MK
-
[ADDRESS_929392] MSI results confirmed using the MSI Analysis System from Promega
 
(
S
ection 3.4
). This test will determine MSI st
atus through the insertion or deletion of 
repeating units in the five nearly monomorphic mononucleotide repeat markers (BAT
-
25, BAT
-
26, MON0
-
27, NR
-
21 and NR
-
24). At least 2 MSI loci are required to be 
evaluable in Cohorts A and C. Patients may be assigned
 
to a new cohort and/or replaced 
based on the Promega test results.
 
With amendment 9, the decision was made to not 
require retesting with Promega if MSI status is confirmed by [CONTACT_270212]. 
 
 
The primary endpoint for Cohort D will be 
response rate. The
 
evaluable population for 
Cohort D includes all subjects who receive at least one dose of MK
-
[ADDRESS_929393] a 
documented mutation burden level measured at 
>
 
2
0 mutations 
per megabase pairs (MB)
 
using the Foundation Medicine (Foundatio
nOne.com) 
targeted sequencing panel
.
 
 
 
13.5
 
Analysis of Secondary Endpoints
 
 
Overall survival (OS)
 
is the time from the first day of study treatment with MK
-
[ADDRESS_929394] 
known date alive. Kaplan
-
Meier curves will be used to summarize OS.
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929395] v1.1 and irRC. Summary statistics will be provided for each cohort 
as well as for each 
tumor type for Cohort C. The analysis will also be conducted 
in 
PD
-
L1+ versus PD
-
L1
-
 
protein expression subgroups.
 
 
PFS is defined as the time from 
the first day of study treatment
 
to the date of 
the first documented tumor progression or death due to any c
ause, 
whichever occurs first. Subjects who did not progress or die will be censored 
on the date of their last evaluable tumor assessment.
 
Kaplan
-
Meier curves 
will be used to summarize PFS.
 
 
ORR is defined as the proportion of subjects whose best overall re
sponse 
(BOR)
 
from baseline is either a CR or PR. BOR is determined by [CONTACT_685597]
-
cancer therapy,
 
whi
chever occurs first. For subjects without 
documented progression or subsequent anticancer therapy, all available 
response designations will contribute to the BOR
 
determination. For subjects 
who continue MK
-
[ADDRESS_929396] documented CR or PR. DOOR and TTOR will be 
evaluated for responders (CR or PR) only. 
 
 
13.6
 
Safety Analysis
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
59
The safety analysis will be performed in all treated subjects. Toxicity will be 
tabulated by [CONTACT_16624]. 
 
 
13.7
 
Biomarker
 
Analysis
 
 
Potential relationships between biomarker data and efficacy or safety 
endpoints will be investigated as part of an analysis plan aimed at identifying 
baseline biomarkers that may be used to prospectively identify subjects likely 
(or not likely) 
to respond toMK
-
[ADDRESS_929397] and immune criteria of 
response
 
and 
PFS. Demographic and 
case
-
history factors will be exami
ned to determine whether stratification or 
adjustments should be made within the subsequent statistical analyses, and 
if necessary, the appropriate stratification or adjustment will be made. 
Biomarkers will be summarized graphically as they relate to effic
acy and 
safety endpoints, as applicable. Summary statistics will be tabulated. The 
relationships between binary measures (e.g. response) and candidate 
biomarkers will be investigated using logistic regression. Associations will be 
summarized in terms of po
int and interval estimates of hazard ratios, odds 
ratios, or other statistics, as appropriate for the analyses completed. Models 
to predict clinical activity based on combinations of biomarkers may also be 
investigated.
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929398] the effectiveness of the proposed method in comparing treatment effects based 
on longitudinal serum biomarkers. This dataset will also help us to develop novel 
statistical methods to better identify subgroups that a
re more responsive to a given 
treatment, where patient subgroup is often defined based on genetic profiles. This work 
will be done in collaboration with the Medical University of South Carolina ([CONTACT_270242]
-
Mayer and Wei Wei).
 
 
Additional post ho
c statistical analyses not specified in the protocol, such as 
alternative modeling approaches may be completed. All analyses described 
in this section are based on the availability of the data.
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
61
REFERENCES
 
 
1. 
Dietmaier W
, 
Wallinger S
, 
Bocker T
, 
Kullmann F
, 
Fishel R
, 
Rüschoff J
. 
Diagnostic
 
mi
crosatellite instability
: 
definition
 
and 
correlation
 
with mismatch repair protein expression. 
Cancer Res.
 
1997: 57:4749
-
56.
 
 
2. 
Boland CR
, 
Thibodeau SN
, 
Hamilton SR
, 
Sidransky D
, 
Eshleman JR
, 
Burt RW
, et al. A 
Nat
ional 
Cancer Institute
 
Workshop
 
on 
Microsatellite Instability
 
for 
cancer
 
detection
 
and 
familial
 
predisposition
: development of international criteria for the determination of 
microsatellite 
instability
 
in colorectal 
cancer
. 
Cancer
 
Res.
 
1998:58:5248
-
57.
 
 
3
. 
Smyrk TC
, Watson P, Kaul K, Lynch HT.
 
Tumor
-
infiltrating lymphocytes are a marker for 
microsatellite instability in colorectal carcinoma. 
Cancer. 2001:91:2417
-
22.
 
 
4
. 
Grogg K
L, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. 
Lymphocyte
-
Rich Gastric Cancer: 
Associations with Epstein
-
Barr Virus, Microsatellite Instability, Histology, and Survival. 
Mod 
Pathol.
 
2003:16:641
-
51.
 
 
5
. 
Leach FS
. 
Microsatellite instability
 
and 
prostate cancer
: 
clinical
 
and 
pathol
ogical
 
implications
. 
Curr Opin Urol.
 
2002:12:407
-
11.
 
 
6
. 
Kouso H
, 
Yoshino I
, 
Miur
a N
, 
Takenaka T
, 
Ohba T
, 
Yohena T
, et al. 
Expression
 
of 
mismatch
 
repair
 
proteins
, 
hMLH1
/
hMSH2
, in 
non
-
small
 
cell
 
lung
 
cancer
 
tissues
 
and its 
clinical
 
significance
. 
J Surg Oncol.
 
2008:98:377
-
83.
 
 
7
. 
Skarda J
, 
Fridman E
, 
Plevova P
, 
Hajduch M
, 
Radova L
, 
Ofek E
, et al. 
Prognostic
 
value
 
of 
hMLH1
 
and 
hMSH2
 
immunohistochemical
 
expression
 
in 
non
-
small
 
cell
 
lung
 
cancer
. A 
tissue
 
microarray
 
study
. 
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
 
2006:150:255
-
9.
 
 
8
. 
Agaram NP
, 
Shia J
, 
Tang LH
, 
Klimstra DS
. 
DNA
 
mismatch
 
repair
 
deficiency
 
in 
ampullary
 
carcinoma
: a 
morphologic
 
and 
immunohist
ochemical
 
study
 
of 
54
 
cases
. 
Am J Clin 
Pathol.
 
2010:133:772
-
80.
 
 
9
. 
Garg K
, 
Leitao MM Jr
, 
Kauff ND
, 
Hansen J
, 
Kosarin K
, 
Shia 
J
, 
Soslow RA
. 
Selection
 
of 
endometrial
 
carcinomas
 
for 
DNA
 
mismatch
 
repair
 
protein
 
immunohistochemistry
 
using 
patient
 
age
 
and 
tumor
 
morphology
 
enhances
 
detection
 
of 
mismatch
 
repair
 
abnormalities
. 
Am J Surg 
Pathol.
 
2009:33:[ADDRESS_929399]. 
Defective DNA 
mismatch repair in long
-
term (> or =3 years) survivors with pancreatic cancer. 
Pancreatology. 
2005:5:220
-
8
.
 
 
11
.
 
Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28(29):4531
-
8.  
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929400], Tamura H, Hirano F, Flies DB, et al. Tumor
-
associated B7
-
H1 promotes T
-
cell apoptosis: a potential mechanism of immune evasion. Nat Med 
2002;8(8):793
-
800.  
 
13
.
 
Sharpe AH, Freeman GJ. The B7
-
CD28 superfamily. Nature 2002;2:11
6
-
26.  
 
14
.
 
Brown JA, Dorfman DM, Ma F
-
R, Sullivan EL, Munoz O, Wood CR, et al. Blockade of 
programmed death
-
1 ligands on dendritic cells enhances T cell activation and cytokine 
production. J Immunol 2003;170:[ADDRESS_929401] in tolerance and autoimmunity. 
Immunol Rev 2010;236:219
-
42.  
 
16
.
 
Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD
-
1 
expressed by [CONTACT_20150]
-
infiltrating immune cells and is associated with poor outcome for patien
ts 
with renal cell carcinoma. Clin Caner Res 2007;13(6):1757
-
61.  
 
17
.
 
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and 
therapeutic potential of the programmed death
-
1 ligand/programmed death
-
[ADDRESS_929402] in 
human pancr
eatic cancer. Clin Cancer Res 2007;13(7):2151
-
7 
 
18
.
 
Gao Q, Wang X
-
Y, Qiu S
-
J, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD
-
L1 
significantly associates with tumor aggressiveness and postoperative recurrence in human 
hepatocellular carcinoma. Cl
in Cancer Res 2009;15(3):971
-
9.   
 
19
.
 
Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed 
cell death 1 ligand 1 and tumor
-
infiltrating CD8+ T lymphocytes are prognostic factors of 
human ovarian cancer. PNAS 2007;104(9):33
60
-
5.  
 
20
.
 
Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression 
of programmed cell death
-
1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 
2010;116:1757
-
66.
 
21
.
 
Fourcade J, Kudela P, Sun Z, Shen H, Land SR,
 
Lenzner D, et al. PD
-
1 is a regulator of NY
-
ESO
-
1
-
specific CD8+ T cell expansion in melanoma patients. J Immunol 2009;182:5240
-
9.  
 
22
.
 
Cai G, Karni A, Oliveira EML, Weiner HL, Hafler DA, Freeman GJ. PD
-
1 ligands, negative 
regulators for activation of naï
ve, memory, and recently activated human CD4+ T cells. Cell 
Immunol 2004;230(2):89
-
98.  
 
23
.
 
Blank C, Mackensen A. Contribution of the PD
-
L1/PD
-
[ADDRESS_929403] to T
-
cell exhaustion: and 
update on implications for chronic infections and tumor evasion. Cancer Immu
nol Immunother 
2007;56:[ADDRESS_929404] immune system and tumor immunotherapy by [CONTACT_4002]
-
L1 blockade. 
PNAS 2002;99(19):[ZIP_CODE]
-
7.  
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
63
25
.
 
Tsushima F, 
Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, et al. Predominant 
expression of B7
-
H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral 
Oncol 2006;42:268
-
74.  
 
26
.
 
Homsi J, Kashani
-
Sabet M, Messina JL, Daud A. Cutaneous melanoma:  prog
nostic factors. 
Cancer Control 2005;12(4):223
-
9..  
 
27
.
 
Korman A, Chen B, Wang C, Wu L, Cardarelli P, Selby M. Activity of anti
-
PD
-
1 in murine 
tumor models: role of "host" PD
-
L1 and synergistic effect of anti
-
PD
-
1 and anti
-
CTLA
-
4 
[Abstract]. J Immunol 2007
;178:48.37
 
28
.
 
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
activity, and immune correlates of Anti

PD
-
1 antibody in cancer. N Engl J Med 2012:doi: 
10.1056/NEJMoa1200690.  
 
29
.
 
Patnaik A, Kang SP, Tolcher AW, Rasco
 
DW, Papadopoulos KP, Beeram M, et al. 2012 ASCO 
Annual Meeting:  Phase I study of MK
-
3475 (anti
-
PD
-
1 monoclonal antibody) in patients with 
advanced solid tumors, 2012.   
 
30
.
 
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved 
survival with ipi[INVESTIGATOR_8612]. N Engl J Med 
2010;363(8):711
-
23.  
 
31
.
 
Chapman PB, Hauschild A, Robert C, Hannen JB, Ascierto P, Larkin J, et al. Improved 
survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 
2011;346(26):2507
-
16.  
 
32
.
 
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et a
l. Ipi[INVESTIGATOR_27606]. N Engl J Med 2011;364(26):2517
-
26.  
 
33
.
 
Bellati F, Visconti V, Napoletano C, Antonilli M, Frati L, Benedetti Panici P, et al. 
Immunology of gynecologic neoplasms: analysis of the
 
prognostic significance of the immune 
status. Curr Cancer Drug Targets 2009;9(4):541
-
65.  
 
34
.
 
Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: 
polarization towards pro
-
tumor immunity. Cytokine Growth Factor Rev 2010;21:3
-
10.  
 
35
.
 
Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, et al. Tumor
-
infiltrating 
lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin 
Oncol 2010;15:552
-
8.  
 
36
.
 
Al
-
Shibli K, Al
-
Saad S, Andersen S, Donnem T,
 
Bremnes RM, Busund L
-
T. The prognistic 
value of intraepi[INVESTIGATOR_270210]3
-
, CD117
-
 
and CD138
-
positive cells in non
-
small cell 
lung carcinoma. APMIS 2010;118:371
-
82.  
 
37
.
 
Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocar
cinoma: 
insights from genetically engineered mouse models of cancer. Cancer Lett 2009;279:1
-
7.  
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
64
38
.
 
Diederichsen ACP, Hjelmborg JvB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of 
the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorec
tal cancer and HLA
-
DR 
expression on tumour cells. Cancer Immunol Immunother 2003;52:423
-
8.  
 
39
.
 
Gao Q, Qiu S
-
J, Fan J, Zhou J, Wang X
-
Y, Xiao Y
-
S, et al. Intratumoral balance of regulatory 
and cytotoxic T cells is associated with prognosis of hepatocellul
ar carcinoma after resection. 
J Clin Oncol 2007;25(18):2586
-
93.  
 
40
.
 
Hillen F, Baeten CIM, van de Winkel A, Creytens D, van der Schaft DWJ, Winnepenninckx 
V, et al. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in 
prima
ry cutaneous melanoma. Cancer Immunol Immunother 2008;57:97
-
106.  
 
41
.
 
Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, et al. CD3+ cells at the 
invasive margin of deeply invading (pT3
-
T4) colorectal cancer and risk of post
-
surgical 
metasta
tsis: a longitudinal study. Lancet Oncol 2009;10:877
-
84.  
 
42
.
 
Li JF, Chu YW, Wang GM, Zhu TY, Rong RM, Hou J, et al. The prognostic value of 
peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase
-
2 
expression in clear cell ren
al cell carcinoma. BJU Intern 2008;103:399
-
405.  
 
43
.
 
Nemolato S, Fanni D, Naccarato AG, Ravarino A, Bevilacqua G, Faa G. Lymphoepi[INVESTIGATOR_99186]
-
like hepatocellular carcinoma: a case report and a review of the literature. World J 
Gastroenterol 2008;14(29):4694
-
6.  
 
44
.
 
Nobili C, Degrate L, Caprotti R, Franciosi C, Leone BE, Trezzi R, et al. Prolonged survival of 
a patient affected by [CONTACT_270236]
-
2 immunotherapy. Report of a c
ase. Tumori 2008;94:426
-
30.  
 
45
.
 
Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, Nakakubo Y, et al. Prognostic 
value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential 
immune response. J Surg Oncol 2003;84:224
-
8
.  
 
46
.
 
Pi[INVESTIGATOR_44822], Welters MJP, van der Burg SH. Tumor
-
specific regulatory T cells in cancer 
patients. Human Immunol 2008;69:241
-
9.  
 
47
.
 
Rao UNM, Lee SJ, Luo W, Mihm Jr. MC, Kirkwood JM. Presence of tumor
-
infiltrating 
lymphocytes and a dominant nodule wi
thin primary melanoma are prognostic factors for 
relapse
-
free survival of patients with thick (T4) primary melanoma: pathologic analysis of the 
E1690 and E1694 intergroup trials. Am J Clin Pathol 2010;133:646
-
53.  
 
48
.
 
Sasaki A, Tanaka F, Mimori K, Inoue H
, Kai S, Shibata K, et al. Prognostic value of tumor
-
infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. EJSO 
2008;34:173
-
9.  
 
49
.
 
Shen Z, Zhou S, Wang Y, Li R, Zhong C, Liang C, et al. Higher intratumoral infiltrated Foxp3+ 
T
reg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable 
gastric cancer. J Cancer Res Clin Oncol 2010;136:1585
-
95.  
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
65
50
.
 
Hiraoka N. Tumor
-
infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. 
Int J Clin Onco
l 2010;15:544
-
51.  
 
51
. 
Brahmer JR, Drake CG, Wollner I, Powderly JD, Pi[INVESTIGATOR_361] J, Sharfman WH, 
et al
. Phase I study 
of single
-
agent anti
-
programmed death
-
1 (MDX
-
1106) in refractory solid tumors: safety, 
clinical activity, pharmacodynamics, and immunologic cor
relates. J Clin Oncol. 2010: 
28:3167
-
75.
 
52
. 
Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer 
medulloblastoma. Science 2011;331:435
-
9.
 
53
. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent 
P
REX2 mutations. Nature 2012:485:502
-
6.
 
54
. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by [CONTACT_270237] 
a lung cancer patient. Nature 2010:465:473
-
7.
 
55
. Timmermann B, Kerick M, Roehr C, et al. Somatic mutation profiles of M
SI and MSS 
colorectal cancer identified by [CONTACT_270238]. PLoS One 2010:5:e15661.
 
56
. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma 
Multiforme. Science 
2008:321:1807
-
12.
 
 
57
. 
Lipson EJ
, 
Sharfman WH
, 
Drake CG
, 
Wollner I
, 
Taube JM
, 
Anders RA
, et al. Durable Cancer 
Regression Off
-
Treatment and Effective Reinduction Therapy with an Anti
-
PD
-
1 Antibody. 
Clin Cancer Res.
 
2013:19:[ADDRESS_929405] and colorectal cancer. Cancer Res. 2008: 68:889
-
92. 
 
 
 
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
66
APPENDIX A
: 
Performance Status Criteria
 
 
ECOG Performance Status Scale
 
Karnofsky Performance Scale
 
Grade
 
Descriptions
 
Percent
 
Description
 
0
 
Normal activity.  Fully active, able 
to carry on all pre
-
disease 
performance without restriction.
 
100
 
Normal, no complaints, no evidence 
of disease.
 
90
 
Able to carry on normal activity; 
minor signs or symptoms of disease.
 
1
 
Symptoms, but
 
ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work).
 
80
 
Normal activity with effort; some 
signs or symptoms of disease.
 
70
 
Cares for 
self, unable to carry on 
normal activity or to do active work.
 
2
 
In bed <50% of the time.  
Ambulatory and capable of all 
self
-
care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.
 
[ADDRESS_929406] of his/her 
needs.
 
50
 
Requires considerable assistance and 
frequent medical care.
 
3
 
In bed >50% of the time.  Capable 
of only limited self
-
care, confined 
to bed or chair more than 50% of 
waking hours.
 
40
 
Disabled, requires special care and 
assistance.
 
30
 
Severely disabled, hospi[INVESTIGATOR_373].  Death not imminent.
 
4
 
100% bedridden.  Completely 
disabled.  Cannot carry on any 
self
-
care.  Totally confined to bed 
or chair.
 
20
 
Very sick, 
hospi[INVESTIGATOR_374]. 
Death not imminent.
 
10
 
Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].
 
5
 
Dead.
 
0
 
Dead.
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
67
APPENDIX B: Foundation One Tumor Mutational Burden (TMB) Testing 
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
68
APPENDIX 
C
: Adverse Event of Clinical Interest (ECI) 
Reporting Form
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, [ADDRESS_929407] (ECI) Reporting Form
 
 
Please notify: 
 
 
 
 
Protocol Title:
 
 
 
Phase 2 Study of MK
-
3475 in Patients with Mic
rosatellite Unstable (MSI) 
Tumors
 
Protocol Number 
(MK
-
3475
-
016):
 
 
Signature [CONTACT_39299]:
 
 
 
 
[INVESTIGATOR_678]:
 
 
Date:
 
 
 
 
Report Type:
 
 
Initial          
Follow
-
up          
Final Follow
-
up    
      
Addendum to:
 
 
 
 
Section A: Subject Information
 
Subject ID:
 
Subject Initial:
 
 
Subject Gender:
 
Male
 
Female
 
 
Section B: Event Information
 
Event diagnosis or symptoms:
 
 
Date of First Dose (
MK
-
3475
):
 
 
Action taken with the study
 
drug (
MK
-
3475
):
 
 
None
 
Interrupted
 
Discontinued
 
Delayed
 
 
Date of Last Dose (
MK
-
3475
) prior to 
Event:
 
 
Number of Total Doses (
MK
-
3475
):
 
 
Event Onset Date:
 
Event 
End Date:
 
 
 
 
Date Event Discovered:
 
 
Relationship to:
 
MK
-
3475
 
Underlying Disease
 
Unrelated
 
 
 
Probably Unrelated
 
 
 
Possible Related
 
 
 
Probably Related
 
 
 
Definitely Related
 
 
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
70
Section C: Brief Description of the Event: (
please include relevant procedures and laboratory values) 
 
 
Section D: Relevant 
Medical History
 
 
Section E: Concomitant Drug (Not related to ECI)
 
Name [CONTACT_658930] F: Comments
 
 
Additional Documents: 
 
Please specify
 
 
 
 
 
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
71
 
APPENDIX 
D
: 
SAE Reporting Form
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
72
Serious Adverse Event Reporting Form
 
 
Please notify: 
 
 
 
 
Protocol Title:
 
 
 
Phase 2 Study of MK
-
3475 in Patients with Microsatellite Unstable (MSI) 
Tumors
 
Protocol Number
 
(MK
-
3475
-
016)
:
 
 
Signature [CONTACT_39299]:
 
 
 
 
[INVESTIGATOR_678]:
 
 
Date:
 
 
 
 
Report Type:
 
Initial   
 
Follow
-
up
 
Final Follow
-
up
 
Death
 
Addendum to:
 
 
Serious Criteria (check all
 
that apply):
 
Death   
 
Life
-
threatening
 
 
Hospi[INVESTIGATOR_685583]: 
 
 
 
 
Hospi[INVESTIGATOR_379]:
 
Date Event 
Discovered:
 
Section A: Subject Information
 
Subject ID:
 
Subject 
Age
:
 
 
Subject Gender:
 
Male
 
Female
 
Section B: Event Information
 
Event diagnosis or 
symptoms:
 
Event Grade:
 
Cause of death (if 
applicable):
 
Event Outcome:
 
 
Not Recovered
 
 
Recovering
 
 
Recovered
 
 
Recovered with sequelae
 
 
Death
 
 
Unknown
 
Event Onset Date
 
(or 
Date of Death)
:
 
Event End Date:
 
Action taken with the study drug 
(
MK
-
3475
):
 
None
 
Interrupted
 
Discontinued
 
Delayed
 
Section C
: 
Study Drug
 
Information
 
 
Date First Dose:
 
 
 
 
 
Number Total Cycles:
 
Date Last Dose:
 

Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
73
Relationship to:
 
MK
-
3475
 
Underlying Disease
 
Unrelated
 
 
 
Probably Unrelated
 
 
 
Possible Related
 
 
 
Probably Related
 
 
 
Definitely Related
 
 
 
Section D
: Brief Description of the Event:
 
 
Section E
: Relevant Medical History
 
 
Section F
: Concomitant Drug (Not related to SAE)
 
Name [CONTACT_658931] F: Comments
 
 
Additional Documents: 
 
Please specify
 
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
74
APPENDIX 
E
: 
Response Evaluation Criteria in Solid Tumors (RECIST) 1.[ADDRESS_929408] is the preferred imaging technique in this 
study.  
 
Disease Parameters
 
 
Measurable disease
:  Measurable lesions are defined as
 
those that can be accurately measured in 
at least one dimension (longest diameter to be recorded) as 
>
[ADDRESS_929409] x
-
ray, as 
>
[ADDRESS_929410] scan, or 
>
[ADDRESS_929411] be 
recorded in 
millimeters
 
(or decim
al fractions of centimeters).
 
 
Note:  Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable unless there is evidence of progression in the irradiated site. 
Malignant 
lymph nodes.
  
To be considered patho
logically enlarged and measurable, a lymph node must 
be 
>
[ADDRESS_929412] scan (CT scan slice thickness recommended to 
be no greater than 5 mm).  At baseline and in follow
-
up, only the short axis will be measured 
and followed.
 
 
Non
-
measurable disease
:  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with 
≥10 to <15 mm short axis), are considered 
non
-
measurable disease.  Bone lesions, leptomeningeal disease, asc
ites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not 
followed by [CONTACT_462]), are considered as non
-
measurable.
 
 
Note:  Cystic lesions that meet the criteria for radiographically defined 
simple cysts should not 
be considered as malignant lesions (neither measurable nor non
-
measurable) since they are, by 
[CONTACT_108], simple cysts.
 
 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet t
he definition of measurability described above. However, if non
-
cystic lesions 
are present in the same patient, these are preferred for selection as target lesions.
 
 
Target lesions:
  
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesio
ns in 
total, representative of all involved organs, should be identified as 
target lesions
 
and recorded and 
measured at baseline.  Target lesions should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all in
volved organs, but in addition should be those that 
lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducible measurement in which circumstance the next 
largest les
ion which can be measured reproducibly should be selected.  A sum of the diameters 
(longest for non
-
nodal lesions, short axis for nodal lesions) for all target lesions will be calculated 
and reported as the baseline sum diameters.  If lymph nodes are to be
 
included in the sum, then 
only the short axis is added into the sum.  The baseline sum diameters will be used as reference to 
further characterize any objective tumor regression in the measurable dimension of the disease.
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
75
Non
-
target lesions
:  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as 
non
-
target lesions 
and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the pre
sence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow
-
up. 
 
 
Evaluation of Target Lesions
 
 
Complete Response (CR)
:
 
Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non
-
target)
 
must have reduction in short axis to <10 mm.
 
 
Partial Response (PR)
: At least a 30% decrease in the sum of the diameters of target lesions, taking 
as reference the baseline sum diameters.
 
 
Progressive Disease (PD)
: At least a 20% increase in the sum of 
the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest 
on study).  In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5
 
mm.  (Note:  the appearance of one or more new lesions is also considered 
progressions).
 
 
Stable Disease (SD)
: Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while 
on study.
 
 
Evaluation of Non
-
Target Lesions
 
 
Complete Response (CR)
:
 
Disappearance of all non
-
target lesions and normalization of tumor 
marker level.  All lymph nodes must be non
-
pathological in size (<10 mm short axis).
 
 
Note:  If tumor markers are 
initially above the upper normal limit, they must normalize for a patient 
to be considered in complete clinical response.
 
 
 
Non
-
CR/Non
-
PD:
 
Persistence of one or more non
-
target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.
 
 
Progressive Disease (PD)
:
 
Appearance of one or more new lesions and/or 
unequivocal progression
 
of existing non
-
target lesions.  
Unequivocal progression
 
should not normally trump target lesion 
status.  It must be representative of overall disease status cha
nge, not a single lesion increase.    
 
 
Although a clear progression of “non
-
target” lesions only is exceptional, the opi[INVESTIGATOR_62484], and the progression status should be confirmed at 
a later time by 
[CONTACT_463] (or Principal Investigator).
 
 
Evaluation of Best Overall Response
 
 
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease 
the smallest measurements 
recorded since the treatment started).  The patient's best response assignment will depend on the 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
76
achievement of both measurement and confirmation criteria.
 
 
For Patients with Measurable Disease (i.e., Target Disease)
 
 
Target 
Lesions
 
Non
-
Target 
Lesions
 
New 
Lesions
 
Overall 
Response
 
Best Overall 
Response when 
Confirmation is 
Required*
 
CR
 
CR
 
No
 
CR
 
>
4 wks. 
Confirmation**
 
CR
 
Non
-
CR/Non
-
PD
 
No
 
PR
 
>
4 wks. 
Confirmation**
 
CR
 
Not evaluated
 
No
 
PR
 
PR
 
Non
-
CR/Non
-
PD/not 
evaluated
 
No
 
PR
 
SD
 
Non
-
CR/Non
-
PD/not 
evaluated
 
No
 
SD
 
Documented at least 
once 
>
4 wks. from 
baseline**
 
PD
 
Any
 
Yes or 
No
 
PD
 
no prior SD, PR or CR
 
Any
 
PD***
 
Yes or 
No
 
PD
 
Any
 
Any
 
Yes
 
PD
 
*
 
See RECIST 1.1 manuscript for further details on what is evidence of 
a new 
lesion.
 
**
 
Only for non
-
randomized trials with response as primary endpoint.
 
***
 
In exceptional circumstances, unequivocal progression in non
-
target 
lesions may be accepted as disease progression.
 
 
Note
:
 
Patients with a global deterioration of health 
status requiring 
discontinuation of treatment without objective evidence of disease 
progression at that time should be reported as “
symptomatic 
deterioration.”
  
Every effort should be made to document the 
objective progression even after discontinuation of
 
treatment.
 
 
Reference
 
 
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. 
Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. 
Verweij. New response evaluation criteria in 
solid tumours: Revised RECIST guideline (version 
1.1).  Eur J Cancer. 2009 Jan;45(2):228
-
47.
 
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
77
A
PPENDIX
 
F
: 
Immune Related Response Criteria
 
 
For all patients who experience disease progression on study, the date noted for of disease 
progression is the time of the scan where it is originally detected, and not the following date of the 
confirmatory scan. 
 
Definitions of measurable and non
-
measura
ble disease 
 
Measurable disease: 
Neoplastic masses that can 
be precisely measured in [ADDRESS_929413] a short
-
axis line
-
length of 
≥ [ADDRESS_929414] perpendicular. 
 
Non
-
measurabl
e 
disease
: Non
-
measurable lesions are those that are not suitable for quantitative 
assessment over time. These include:
 
1)
 
Neoplastic masses that are too small to measure, because their longest uninterrupted diameter 
or longest perpendicular are less than 
10 mm.
 
2)
 
Neoplastic masses whose boundaries cannot be distinguished.  This includes masses which 
cannot be 
demarcated
 
from surrounding tissue because of inadequate contrast, masses with 
overly complex morphology, or those with highly heterogeneous tissue 
composition.  
 
3)
 
Other types of lesions that are confidently felt to represent neoplastic tissue, but difficult to 
quantify in a reproducible manner. These include bone metastases, leptomeningeal metastases, 
malignant ascites, pleural/pericardial effusion
s, inflammatory breast disease, lymphangitis 
cutis/pulmonis, cystic lesions, 
ill
-
defined
 
abdominal masses, etc.
 
For irRC, only target lesions selected at baseline and measurable new lesions are taken into 
account. 
 
At the baseline tumor assessment, the sum
 
of the products of the two largest perpendicular 
diameters
 
(SPD) of all 
index lesions 
(five lesions per organ, up to 10 visceral lesions and five 
cutaneous index lesions) is calculated.  
 
At each subsequent tumor assessment, the SPD of the index lesions a
nd of new, measurable 
lesions
 
(
≥ 5 X 5 mm; up to 5 new lesions per organ: 5 new cutaneous lesions and 10 visceral lesions) are 
added together to provide the total time
-
point 
tumor burden.
 
 
 
Phase 2 Study of 
MK
-
3475 in Patients with Microsatellite Unstable (MSI) Tumors
 
Amendment 1
3
/ Version 
1
4
/ 
August 
7, 2020
 
78
Overall response using irRC:
 

 
Complete Response (irCR): 
Complete di
sappearance of all tumor lesions (whether 
measureable or not, and no new lesions).  CR must be confirmed by [CONTACT_491], consecutive 
assessments made no less than [ADDRESS_929415] documented. 
 

 
Partial Response (irPR): 
Decrease in SPD of 50% or grea
ter by a consecutive assessment 
at least [ADDRESS_929416] documentation. 
 

 
Stable 
Disease
 
(irSD): 
Failure to meet criteria for irCR or irPR, in absence of irPD.  
 

 
Progressive Disease (irPD): 
At least 25% increase in SPD relative to nadir (minimum 
recorde
d tumor burden) Confirmation by a repeat, consecutive assessment no less than [ADDRESS_929417] documented.  
 
Please note other key differences between irRC and the original WHO criteria:
 
New measurable lesions will be incorporated into the SPD 
 
New non measurable lesions do not define progression but preclude irCR
 
Non
-
index lesions contribute to defining irCR (complete disappearance required).
 
REFERENCE
 
IrRC for the current protocol is adopted from the following reference:
 
Wolchok, JD, Hoos, A, 
O’Day S, et al., Guidelines for the Evaluation of Immune Therapy Activity 
in Solid Tumors: Immune
-
Related Response Criteria. Clinical Cancer Research, 2009 Dec 
1;15(23):7412
-
20.  Epub 2009 Nov 24
.
 
 
 
 